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A B S T R A C T
Background
Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is a chronic progressive or relapsing and remitting disease that
usually causes weakness and sensory loss. The symptoms are due to autoimmune inflammation of peripheral nerves. CIPD affects
about 2 to 3 per 100,000 of the population. More than half of affected people cannot walk unaided when symptoms are at their worst.
CIDP usually responds to treatments that reduce inflammation, but there is disagreement about which treatment is most effective.
Objectives
To summarise the evidence fromCochrane systematic reviews (CSRs) and non-Cochrane systematic reviews of any treatment for CIDP
and to compare the effects of treatments.
Methods
We considered all systematic reviews of randomised controlled trials (RCTs) of any treatment for any form of CIDP. We reported their
primary outcomes, giving priority to change in disability after 12 months.
Two overview authors independently identified published systematic reviews for inclusion and collected data. We reported the quality
of evidence using GRADE criteria. Two other review authors independently checked review selection, data extraction and quality
assessments.
On 31 October 2016, we searched the Cochrane Database of Systematic Reviews, the Database of Abstracts of Reviews of Effects (in
theCochrane Library), MEDLINE, Embase, and CINAHL Plus for systematic reviews of CIDP. We supplemented the RCTs in the
existing CSRs by searching on the same date for RCTs of any treatment of CIDP (including treatment of fatigue or pain in CIDP), in
the Cochrane Neuromuscular Specialised Register, CENTRAL, MEDLINE, Embase, and CINAHL Plus.
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Main results
Five CSRs met our inclusion criteria. We identified 23 randomised trials, of which 15 had been included in these CSRs. We were
unable to compare treatments as originally planned, because outcomes and outcome intervals differed.
Corticosteroids
It is uncertain whether daily oral prednisone improved impairment compared to no treatment because the quality of the evidence
was very low (1 trial, 28 participants). According to moderate-quality evidence (1 trial, 41 participants), six months’ treatment with
high-dose monthly oral dexamethasone did not improve disability more than daily oral prednisolone. Observational studies tell us that
prolonged use of corticosteroids sometimes causes serious side-effects.
Plasma exchange
According to moderate-quality evidence (2 trials, 59 participants), twice-weekly plasma exchange produced more short-term improve-
ment in disability than sham exchange. In the largest observational study, 3.9% of plasma exchange procedures had complications.
Intravenous immunoglobulin
According to high-quality evidence (5 trials, 269 participants), intravenous immunoglobulin (IVIg) produced more short-term im-
provement than placebo. Adverse events were more common with IVIg than placebo (high-quality evidence), but serious adverse events
were not (moderate-quality evidence, 3 trials, 315 participants). One trial with 19 participants provided moderate-quality evidence of
little or no difference in short-term improvement of impairment with plasma exchange in comparison to IVIg. There was little or no
difference in short-term improvement of disability with IVIg in comparison to oral prednisolone (moderate-quality evidence; 1 trial, 29
participants) or intravenous methylprednisolone (high-quality evidence; 1 trial, 45 participants). One unpublished randomised open
trial with 35 participants found little or no difference in disability after three months of IVIg compared to oral prednisone; this trial
has not yet been included in a CSR. We know from observational studies that serious adverse events related to IVIg do occur.
Other immunomodulatory treatments
It is uncertain whether the addition of azathioprine (2 mg/kg) to prednisone improved impairment in comparison to prednisone alone,
as the quality of the evidence is very low (1 trial, 27 participants). Observational studies show that adverse effects truncate treatment
in 10% of people.
According to low-quality evidence (1 trial, 60participants), compared to placebo,methotrexate 15mg/kgdidnot allowmore participants
to reduce corticosteroid or IVIg doses by 20%. Serious adverse events were no more common with methotrexate than with placebo,
but observational studies show that methotrexate can cause teratogenicity, abnormal liver function, and pulmonary fibrosis.
According to moderate-quality evidence (2 trials, 77 participants), interferon beta-1a (IFN beta-1a) in comparison to placebo, did not
allow more people to withdraw from IVIg. According to moderate-quality evidence, serious adverse events were no more common with
IFN beta-1a than with placebo.
We know of no other completed trials of immunosuppressant or immunomodulatory agents for CIDP.
Other treatments
We identified no trials of treatments for fatigue or pain in CIDP.
Adverse effects
Not all trials routinely collected adverse event data; when they did, the quality of evidence was variable. Adverse effects in the short,
medium, and long term occur with all interventions. We are not able to make reliable comparisons of adverse events between the
interventions included in CSRs.
Authors’ conclusions
We cannot be certain based on available evidence whether daily oral prednisone improves impairment compared to no treatment.
However, corticosteroids are commonly used, based on widespread availability, low cost, very low-quality evidence from observational
studies, and clinical experience. The weakness of the evidence does not necessarily mean that corticosteroids are ineffective. High-dose
monthly oral dexamethasone for six months is probably nomore or less effective than daily oral prednisolone. Plasma exchange produces
short-term improvement in impairment as determined by neurological examination, and probably produces short-term improvement in
disability. IVIg produces more short-term improvement in disability than placebo and more adverse events, although serious side effects
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are probably no more common than with placebo. There is no clear difference in short-term improvement in impairment with IVIg
when compared with intravenous methylprednisolone and probably no improvement when compared with either oral prednisolone or
plasma exchange. According to observational studies, adverse events related to difficult venous access, use of citrate, and haemodynamic
changes occur in 3% to17% of plasma exchange procedures.
It is uncertain whether azathioprine is of benefit as the quality of evidence is very low. Methotrexate may not be of benefit and IFN
beta-1a is probably not of benefit.
We need further research to identify predictors of response to different treatments and to compare their long-term benefits, safety
and cost-effectiveness. There is a need for more randomised trials of immunosuppressive and immunomodulatory agents, routes of
administration, and treatments for symptoms of CIDP.
P L A I N L A N G U A G E S U M M A R Y
Overview of all systematic review of all treatments for chronic inflammatory demyelinating polyradiculoneuropathy (CIDP)
Review question
What can we learn from summarising the evidence from systematic reviews on treatments for Chronic Inflammatory Demyelinating
Polyradiculoneuropathy (CIDP)? Is any treatment more or less effective and safe than another?
Background
CIDP is a long-term condition, in which symptoms can steadily worsen over time or show periods of improvement and relapse. People
usually have weakness and numbness due to inflammation of nerves (nerves affected are outside the spinal cord and brain). CIDP
affects about 2 to 3 per 100,000 of the population and can be disabling. More than half of affected people cannot walk unaided when
symptoms are at their worst. Treatments directed at reducing the inflammation usually help but there is no clear evidence favouring
one commonly used treatment over another.
Methods
We searched five databases for all systematic reviews and randomised controlled trials (RCTs) until October 2016. We judged that
five Cochrane systematic reviews (CSRs) provided the best evidence and identified 23 randomised trials, of which 16 have so far been
included in CSRs. We assessed the quality of their included evidence.
Key results and quality of the evidence
The evidence from randomised trials is as follows.
1. It is uncertain whether daily oral prednisone (an anti-inflammatory corticosteroid) improved weakness and sensation (numbness)
compared to no treatment, as the evidence is of very low quality. We know that corticosteroids have a significant risk of serious side
effects during prolonged use.
2. High-dose monthly oral dexamethasone (a more powerful corticosteroid) for six months was probably no more or less effective than
daily oral prednisolone.
3. Plasma exchange probably produced significantly more short-term improvement in disability than dummy exchange. In the largest
observational study, 3.9% of plasma exchange procedures had complications.
4. IVIg produced significantly more short-term improvement in disability than placebo. Adverse events were more common with IVIg
than placebo but serious adverse events were probably no more common than with placebo. Other, lower-quality studies, not eligible
for inclusion here, report that serious adverse effects can occur with IVIg.
5. There was no clear difference in short-term improvement of impairment with plasma exchange as compared to IVIg.
6. There was probably little or no difference in short-term improvement of disability with IVIg in comparison to oral prednisolone
and there was little or no difference in comparison to intravenous methylprednisolone. Corticosteroids are much more widely available
than IVIg, and are cheaper and easier to use.
3Treatments for chronic inflammatory demyelinating polyradiculoneuropathy (CIDP): an overview of systematic reviews (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
7. It is uncertain whether low-dose azathioprine added to prednisone improved impairment over prednisone alone, because the quality
of evidence is very low. Adverse events were not reported but observational studies show that side effects prevent 10% of people from
continuing treatment.
8. Methotrexate may have no benefit over placebo in number of participants able to reduce their corticosteroid or IVIg dose by 20%.
Serious adverse events were probably no more common with methotrexate than with placebo. We know from other types of study that
methotrexate has serious side-effects, including damage to fetuses, liver function abnormalities and scarring of the lung.
9. Interferon beta-1a (IFN beta-1a), compared to placebo, probably does not allowmore people to withdraw from IVIg. Serious adverse
events were probably no more common with IFN beta-1a than with placebo in the two studies of this intervention.
10. There have been no other completed trials of medicines that suppress or change immune responses or that treat fatigue or pain in
CIDP.
We need further research on predictors of response to different treatments, on long-term benefits, and of cost-effectiveness. We need
more RCTs of medicines that suppress or change immune responses and treat symptoms of pain and fatigue in CIDP, and better ways
to collect information on adverse events.
This review is up to date to October 2016.
B A C K G R O U N D
Description of the condition
Chronic inflammatory demyelinating polyradiculoneuropathy
(CIDP) is a chronic progressive or relapsing and remitting disease
that usually causes weakness, sensory loss, and neuropathic pain
in the limbs (Vallat 2010). It is caused by inflammation of the
peripheral nervous system that damages the myelin sheaths that
insulate nerve fibres. This process produces ’demyelination’ within
affected nerves, which slows and can block signal conduction. Al-
though repeated episodes of demyelination and remyelination are
the predominant pathology, the inflammation also damages the
axons in the core of nerve fibres, which can cause the axons to de-
generate. The motor and sensory spinal nerve roots and peripheral
nerves are most often affected. The cranial nerves that control eye
movements and facial, swallowing, and speech muscles are less of-
ten involved. CIDP usually spares the nerves that supply muscles
of respiration and the autonomic nerves that control the bladder,
bowel, and circulation. CIDP often causes chronic fatigue.
The diagnosis ismade by a combination of clinical signs and symp-
toms, evidence of demyelination on nerve conduction tests, and
by excluding other causes. Sometimes supportive tests, such as
cerebrospinal fluid analysis, magnetic resonance imaging of spinal
nerve roots and nerve trunks, nerve biopsy, and therapeutic trials
of immunomodulating agents, help confirm the diagnosis. Several
diagnostic criteria have been proposed. The most widely accepted
criteria used in recent clinical trials rely on clinical history, exami-
nation, nerve conduction evidence, and exclusion of other causes
(Van den Bergh 2010).
The prevalence of CIDP ranges between one and nine people
with CIDP per 100,000 population in different studies, withmost
studies reporting two to three people per 100,000 (Mahdi-Rogers
2010). The condition was 1.4 to 4.7 times more common in
men than women in eight population-based studies that reported
sex ratios. The average age of onset in the four population-
based studies that provided these data was 48 years to 58 years
(Mahdi-Rogers 2010). CIDP is rare in children and becomes more
common with age, reaching peak prevalence in the eighth decade.
In one population-based study, nine of 62 people (14.5%) had
a progressive course, 44 people (71%) had a relapsing-remitting
course, and nine people (14.5%) had a monophasic disease course
(Mahdi-Rogers 2010). According to a summary of series by Vallat
2010, other studies find that 7% to 50% of people with CIDP
have monophasic or progressive courses, and 20% to 35% of peo-
ple have a relapsing-remitting course.
CIDP can be severely disabling, but the degree of disability
varies. On the prevalence day in the population-based study
(Mahdi-Rogers 2010), 28 people (68.2%) walked independently,
10 people (24.4%) required unilateral support and three people
(7.3%) required bilateral support to walk 10 metres. No-one in
the study needed a wheelchair, although in other series some peo-
ple did. At nadir, 31 people (75.6%) had disability in their upper
limbs, 17 people (41.5%) could walk independently, 11 people
(26.8%)neededunilateral support, six people neededbilateral sup-
port and seven people used a wheelchair. Most commonly, CIDP
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causes progressive weakness leading to a need for aids to walk,
which is often followed by improvement with treatment. How-
ever, repeated or prolonged treatment may be needed. In the pop-
ulation-based study mentioned, 64 of 84 people (76.2%) required
treatment and 51 people (79.7%) improved with at least one of
the main treatments: corticosteroids, intravenous immunoglobu-
lin (IVIg), or plasma exchange. Treatment of CIDP is expensive,
especially when IVIg is used. According to Blackhouse 2010, the
cost per quality-adjusted life year (QALY) of using IVIg rather than
corticosteroids was CAD696,598 (approximately USD535,800).
The causes of CIDP are attributed to immune mechanisms. Dur-
ing active disease, pathological study of affected nerve roots and
trunks shows inflammation and stripping of the myelin sheaths
from the axons bymacrophages. The inflammation is probably due
to an autoimmune process. There is debate about the relative roles
of antibodies and T-lymphocytes directed against the Schwann
cell, myelin, or both. There is some evidence of impairment of
the regulatory T and B cells that normally effect autoimmune re-
sponses (Vallat 2010; Mathey 2015). Specific serum autoantibod-
ies, which include antibodies to gangliosides and other compo-
nents of myelin, are present only in a small proportion of people
with CIDP. People who have autoantibodies to components of the
node of Ranvier, such as contactin-1/contactin-associated protein
1 (CNTN1/CASPR), or neurofascin IgG4 autoantibodies, seem
to have more aggressive disease and a poorer response to treatment
(Querol 2014).
Description of the interventions
Treatments aimed at the underlying disease
The common two first-line treatments for CIDP are corticos-
teroids, which are given daily as tablets, or every four weeks as
tablets or intravenous infusions, and immunoglobulin, which is
usually given intravenously over two to five days for the first dose
and then over one day every two to eight weeks for follow-up doses.
Corticosteroids are anti-inflammatory drugs used in many types
of inflammatory conditions, such as asthma and arthritis. They are
widely available and inexpensive, but long-term use risks poten-
tially serious side-effects, including high blood pressure, diabetes
mellitus, obesity, thinning of the bones, and cataracts (Bromberg
2004).
Immunoglobulin has both different risks and different advantages.
It is extracted from the plasma of several thousand blood donors
and purified to reduce the risk of transmitting infections. It is
in limited supply, not always available, and extremely expensive.
Immunoglobulin causes two categories of adverse events: tran-
sient and long-lasting. Infusions are commonly associated with
several days or a week of headache, nausea, rash, or influenza-
like symptoms, Some people develop signs of meningeal irrita-
tion. In contrast, serious or long-lasting side-effects are rare. They
include venous thrombosis, which can cause infarctions in im-
portant organs such as the brain, lungs, and heart; severe skin re-
actions; haemolytic anaemia; and kidney failure (Eftimov 2013).
Immunoglobulin is most often administered intravenously, but
there is an increasing trend to subcutaneous administration, which
is generally more convenient for patients.
Plasma exchange is the third first-line treatment. It involves re-
moving the patient’s blood, separating the plasma from the cells,
replacing the plasma with a substitute, and returning the cells and
plasma substitute to the patient. Modern machines can replace
the whole plasma volume in a few hours. A course of about five
treatments on consecutive or alternate days is commonly used to
initiate treatment, but regimens vary, and single exchanges every
few weeks are sometimes used for long-term treatment. Plasma
exchange is usually safe, although there are side-effects, such as
bleeding, infections, and injuries arising from inserting large tubes
into veins. Its main drawbacks are inconvenience, expense, and
limited availability (Kiprov 2001).
When first-line treatments are inadequate, neurologists often pre-
scribe immunosuppressant or other immunomodulatory agents.
Those most commonly used for CIDP are azathioprine, cy-
clophosphamide, ciclosporin, and methotrexate. The drugs can
be given orally, although cyclophosphamide is also given intra-
venously and methotrexate by intramuscular or subcutaneous in-
jection. They all reduce the white cell count and increase the risk
of infection. A small long-term increased risk of cancer is also
a concern. Individual agents have idiosyncratic side-effects. For
instance, azathioprine can cause hypersensitivity reactions, cyclo-
phosphamide hair loss, and ciclosporin kidney failure or hyperten-
sion. Methotrexate can harm fetal growth and cause liver dysfunc-
tion. Mycophenolate mofetil can cause diarrhoea and abdominal
pain. Newer immunosuppressant drugs that target specific com-
ponents of the immune system include rituximab, which depletes
circulating B cells, and fingolimod, which prevents activated T
cells from leaving lymph nodes. The potential benefits of each
treatment have to be balanced against possible harms, and the risk
of non-treatment or other treatment options (Markvardsen 2013).
Treatments of symptoms
In addition to considering treatments for underlying disease pro-
cesses, we planned to provide an overview of reviews of treatments
for symptoms of CIDP, including neuropathic pain and fatigue.
Drugs that have undergone trials as treatments for neuropathic
pain include the tricyclic drug amitriptyline (Saarto 2007) and
drugs that bind to the alpha-2-delta calcium channel, gabapentin
(Moore 2014) and pregabalin (Moore 2009). These are given
orally. Tricyclics are inexpensive and widely available. Drugs and
exercise have been used to treat fatigue in peripheral neuropathy
(White 2014). This overview aimed to focus on reviews and trials
specific to CIDP.
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How the intervention might work
Corticosteroids, IVIg, and other immunomodulatory therapies
are believed to treat CIDP by inhibiting one or many immune
components of its presumed autoimmune inflammatory process.
The mechanisms are incompletely understood, in part because
the mechanisms of nerve damage in CIDP are themselves not
understood (Vallat 2010;Mathey 2015). The respective Cochrane
Systematic Reviews (CSRs) describe in more detail the ways in
which corticosteroids, IVIg, and immunosuppressant drugs are
believed to work.
• Corticosteroids suppress multiple genes that are activated in
chronic inflammatory diseases, mainly through binding of
liganded glucocorticoid receptors to coactivators and recruitment
of histone deacetylase-2 (HDAC2) to the activated transcription
complex. Higher concentrations of corticosteroids also interact
with DNA recognition sites to activate transcription of anti-
inflammatory genes.
• Pooled immunoglobulins have multiple modes of action.
They interfere with activity of the complement system, which
carries out immune-mediated cell damage, and perhaps compete
with nerve-targeting autoantibodies believed to be present in
CIDP.
• Plasma exchange is thought to work by removing antibodies
and other small molecules, such as chemokines, that can affect T
cell function.
• Interferon beta (IFN beta) has multiple actions on the
immune system which tend to down-regulate harmful immune
responses (Kieseier 2011).
• Exercise might help fatigue in CIDP by a combination of
improving aerobic fitness, strengthening relevant muscle groups,
and positive psychological effects.
Why it is important to do this overview
Treatment of the underlying disease in CIDP is covered by four
CSRs, on corticosteroids (Hughes 2015), IVIg (Eftimov 2013),
plasma exchange (Mehndiratta 2015), and other immunosuppres-
sive and immunoregulatory drugs (Mahdi-Rogers 2013). Some
people with CIDP have abnormal proteins called paraproteins
in their blood. Stork 2015, the CSR of treatment for IgA and
IgG paraproteinaemic neuropathy, included one relevant trial.
CIDP treatment may have been included in other CSRs or non-
Cochrane systematic reviews, for instance of neuropathic pain
(Saarto 2007; Moore 2009; Moore 2014), fatigue in peripheral
neuropathy (White 2014), or exercise for peripheral neuropa-
thy (White 2004). Drawing together the reviews in this overview
makes their combined information more accessible to people with
CIDP, healthcare professionals, and researchers, and identifies top-
ics for targeting future research.
O B J E C T I V E S
To summarise the evidence fromCochrane systematic reviews and
non-Cochrane systematic reviews of any treatment for chronic
inflammatory demyelinatingpolyradiculoneuropathy (CIDP) and
to compare the effects of treatments.
M E T H O D S
Criteria for considering reviews for inclusion
Types of reviews
In accordance with the advice on overviews of reviews in the
Cochrane Handbook for Systematic Reviews of Interventions (Becker
2011), we considered all Cochrane Systematic Reviews (CSRs)
and non-Cochrane systematic reviews of randomised controlled
trials (RCTs) of any treatment for chronic inflammatory demyeli-
nating polyradiculoneuropathy (CIDP). We did not include non-
systematic reviews.We defined systematic reviews according to the
Cochrane Handbook for Systematic Reviews of Interventions as those
having:
• pre-defined objectives;
• pre-defined criteria for eligibility of evidence;
• an objective systematic search for evidence applying
predetermined inclusion and exclusion criteria; and
• explicit and systematic methods for synthesising evidence
which attempt to reduce bias (Higgins 2011).
When we found an RCT of another therapy for which a plausible
rationale or empirical basis existed that had not been included
in a CSR, we noted the RCT in our overview. We also notified
Cochrane Neuromuscular so that the trial can be considered for
inclusion in a new or existing CSR and then subsequently in later
updates of this overview.
Types of participants
We included reviews of all forms of CIDP approximating to the
definite, probable, and possible diagnostic criteria in the Euro-
pean Federation of Neurological Societies/Peripheral Nerve Soci-
ety (EFNS/PNS) guideline (Van den Bergh 2010). If reviews used
other criteria we noted this. There is some evidence that patients
who have CIDP associated with paraproteins have different nat-
ural history and treatment responses than non-paraproteinaemic
cases. We considered including those with IgG or IgA parapro-
teins, provided that they fulfilled the clinical and electrophysio-
logical criteria of the EFNS/PNS guideline for CIDP. Such partic-
ipants have been considered in a separate CSR (Stork 2015). We
excluded studies of people with IgM paraproteins because their
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neuropathy has a distinctive pathogenesis, and responds differ-
ently to treatment (Lunn 2016). We excluded people with para-
neoplastic CIDP-like illness associated with malignancy.
Some RCTs and reviews included a few participants with IgM
paraproteins or malignancy. We attempted to exclude the results
from these participants. If this was not possible and less than five
per cent of participants in a trial had either of these exclusion crite-
ria, we included the trial. If more than five per cent of participants
had these causes, we excluded the trial from our primary analysis
but included it in a sensitivity analysis.
If systematic reviews also included trials involving participants
with forms of peripheral nerve disease other thanCIDP, we tried to
obtain the results of participants with CIDP alone. If this was not
possible, and more than 95% of participants fulfilled the inclusion
criteria for this overview, we included the trial. If there were fewer
than 95% of participants with CIDP we would have excluded
the trial from our primary analysis but included it in a sensitivity
analysis.
Types of interventions
We planned to include all interventions for CIDP, whether phar-
macological or physical.We considered treatments of both the un-
derlying disease process and of two important CIDP symptoms,
pain and fatigue.
Types of outcomes
In the narrative part of this overview, we reported the outcomes
reported in the individual CSRs. We gave priority to “change in
disability after 12 months” as the primary efficacy outcome, with
change after six months as an alternative. We also reported short-
term outcomes after periods of two weeks to six months, since
most trials only reported these short-term outcomes. The scales
used must have been validated as having good reproducibility,
face validity and correlation with other scales measuring the same
attribute. Recent studies have used the Inflammatory Neuropa-
thy Cause and Treatment (INCAT) scale (Hughes 2001), Over-
all Disability Sum Score (ODSS) (Merkies 2002), and Overall
Neuropathy Limitations Scale (ONLS) (Graham 2006). Earlier
studies have used the Modified Rankin Scale (Bamford 1989) and
Guillain-Barré Syndrome Disability Scale (Hughes 1978).
The preferred secondary efficacy outcomes were change in im-
pairment scores and in quality of life. The scales used must have
been validated as having good reproducibility, face validity and
correlation with other scales measuring the same attribute. We
anticipated that most studies would have included the Medical
Research Council (MRC) sum score (Kleyweg 1991) and a sen-
sory sum score (Merkies 2000), or the Mayo Clinic Neuropathy
Impairment Scale (NIS) (Dyck 2005).
We reported serious adverse events, defined as those requiring pro-
longed hospitalisation or which were fatal at any time during treat-
ment or within a biologically plausible time after treatment cessa-
tion. We expected all trials to have collected these events and sys-
tematic reviews to have reported them. We also reported adverse
events which, although not serious, could influence treatment
choices. Examples include diabetes mellitus (relevant for corticos-
teroids), skin rash (IVIg) and abnormal liver function (methotrex-
ate).
Search methods for identification of reviews
On 31 October 2016, we searched the Cochrane Database of
Systematic Reviews (CDSR 2012, Issue 12) and the Database of
Abstracts of Reviews of Effects (DARE 2015, Issue 2) (in The
Cochrane Library), MEDLINE (January 1966 to October 2016),
Embase (January 1980 toOctober 2016) and CINAHL Plus (Jan-
uary 1937 to October 2016) for systematic reviews of CIDP. We
supplemented the RCTs in the existing CSRs by searching for
RCTs of any treatment of CIDP which included treatment of
fatigue or pain in CIDP, in the Cochrane Neuromuscular Spe-
cialised Register (31 October 2016), Cochrane Central Register of
Controlled Trials (CENTRAL) (31 Ocober 2016 in the Cochrane
Register of Studies Online), MEDLINE (January 1966 to October
2016), Embase (January 1980 to October 2016) and CINAHL
Plus (January 1937 to October 2016).
The detailed search strategies are in the appendices: Appendix
1 (DARE), Appendix 2 (MEDLINE), Appendix 3 (Embase),
Appendix 4 (CINAHL Plus), Appendix 5 (Cochrane Neuromus-
cular Specialised Register), and Appendix 6 (CENTRAL).
Data collection and analysis
RACH,MPTL, and IvS completed the first draft of this Overview
of Reviews. To reduce the risk of bias arising from review author-
ship, trial authorship, or financial conflicts of interest, two inde-
pendent authors (ALO and CC) extensively checked and edited
the review.
Selection of reviews
Two overview authors (RACH and MPTL or INvS) first inde-
pendently selected systematic reviews for inclusion in April 2014.
They would have resolved disagreements by reference to a third
overview author, but there were no disagreements. CC and ALO
subsequently independently checked the search results and an
updated search and selected any new systematic reviews to be
included. These authors retained the systematic reviews already
identified, unless a review had been updated in the interim. The
overview authors included only the most up-to-date version of
each review.
7Treatments for chronic inflammatory demyelinating polyradiculoneuropathy (CIDP): an overview of systematic reviews (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Data extraction and management
Two overview authors (CHC and ALO) independently collected
data from published systematic reviews with a data collection form
designed specifically to include all the data needed. We contacted
the review authors or extracted data from the relevant trials our-
selves if information was lacking. ALO and CC checked the data.
Assessment of methodological quality of included
reviews
The two authors of this overview update (CHC and ALO) inde-
pendently assessed the methodological quality of each included
review. For this purpose they used the Assessing the Methodolog-
ical Quality of Systematic Reviews (AMSTAR) tool developed by
Shea 2007, which has been shown to have acceptable inter-rater
agreement, construct validity and feasibility (Shea 2009). They
reached agreement by discussion.
We reported the assessment of the review authors about the quality
of their included evidence according to GRADE criteria. GRADE
has become the method preferred by Cochrane for evaluating the
quality of evidence, and by many guideline bodies for assessing
the strength of recommendations (GRADE 2008; Guyatt 2008).
Assessments of quality of evidence can be ’high’, ’moderate’, ’low’
or ’very low’. Assessments are based on five factors that can decrease
the quality level of the body of evidence and three that can increase
the quality level. Reasons to downgrade RCTs from high quality
are: 1. risk of bias, 2. indirectness of evidence, 3. unexplained
heterogeneity, 4. imprecision (wide CIs), and 5. a high probability
of publicationbias. Reasons to upgrade evidence are 1. a large effect
size, 2. when “all plausible confounding factors would reduce a
demonstrated effect or suggest a spurious effect when results show
no effect” and 3. a dose-response gradient (Schünemann 2011).
If the grading of the strength of evidence by the original review
authors seemed tous questionable, we adjusted the grade to achieve
consistency between reviews, and explained our reasons.
Data synthesis
We anticipated that the principal method for presenting data from
the constituent systematic reviews would be a narrative review.
We reported the evidence for each intervention from each review
and its strength, estimated using the GRADE approach. If we had
found more than one eligible review of a particular intervention
and the conclusions agreed, we would have reported this. Where
the conclusions differed we would have explored the reasons for
any difference in relation to the AMSTAR scores of the included
reviews. In fact there were no other eligible reviews (see below).
Appendix 7 details methods for use if a network meta-analysis had
been possible, as described in the protocol (Hughes 2013).
R E S U L T S
Results of the search
The searches identified potential RCTs and systematic reviews.
The total number of papers found in each database was 658 in
MEDLINE, 299 in Embase, 3 in CINAHL Plus, 110 in the
CochraneNeuromuscular SpecialisedRegister, 130 inCENTRAL
and 4 in DARE. See Figure 1.
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Figure 1. Study flow diagram.We are unable to calculate numbers of papers following deduplication and
numbers reviewed in full text, as different authors reviewed several searches during development of the
overview.
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Description of included reviews
We selected the most recent updates of Cochrane System-
atic Reviews (CSRs) of corticosteroids (Hughes 2015), intra-
venous immunoglobulin (IVIg) (Eftimov 2013), plasma exchange
(Mehndiratta 2015), and other immunomodulatory treatments
(Mahdi-Rogers 2013) for treating chronic inflammatory de-
myelinating polyradiculoneuropathy (CIDP) for inclusion in this
overview. In accordance with our protocol we also included the
most recent update of a CSR of treatment for neuropathy associ-
ated with IgA and IgG paraproteins (Stork 2015), but not those
associated with IgM paraproteins (Lunn 2016). All the identi-
fied CSRs fulfilled the inclusion criteria for this overview and re-
ceived favourable answers to all questions in the Assessing the
MethodologicalQuality of Systematic Reviews (AMSTAR) check-
list whenever applicable (Table 1). We inspected non-Cochrane
reviews published since 2004 if the title and abstract suggested
theymight have fulfilled the inclusion criteria. However, none ful-
filled the criterion of having pre-defined objectives (Table 2), thus
we did not include them.
Search for additional randomised controlled trials
Two review authors (RACH andMPTL) scrutinised the titles and
abstracts retrieved by the search for this review. They identified
22 completed trials. They detected one additional trial in one of
the parent reviews that was not retrieved by this search (Dyck
1991). Thus, the overview authors considered 23 trials (see Table
3). Of these, two trials of IVIg were excluded from the CSRs and
from this review because of a high risk of bias: one because it
randomised participants whowere known responders to IVIg (Van
Doorn 1990) and one because 50% of participants were lost to
follow-up (Zinman 2005). Six completed trials were not included
in any CSR. We mentioned these in the Discussion. They are:
1. An open randomised trial comparing corticosteroids and
IVIg that had been presented only in abstract form, but for
which the investigator provided results (Camdessanch 2013).
2. A randomised trial comparing gullong tongluo capsule with
no treatment (Hu 2009);
3. A trial of lipoic acid NCT00962429;
4. A trial testing 3,4-diaminopyridine for four days (Russell
1995);
5. A comparative trial of two brands of IVIg (Kuitwaard
2010); and
6. A trial comparing IVIg with subcutaneous immunoglobulin
(Markvardsen 2013).
Thus altogether the Results section of this overview included 15
randomised controlled trial (RCTs) described in five CSRs.
In addition, sponsors abandoned two trials of IVIg after publica-
tion of their designs but before randomisation started; these were
Lee 2010 and the POINT trial (Cornblath 2010). Three other
trials are still in progress (Table 4).
Two other overview update authors (CHC and ALO) indepen-
dently scrutinised the titles and abstracts retrieved by the search
for this overview. They identified no other new completed trials
and agreed the 15 RCTs for inclusion.
Effect of interventions
Corticosteroids
No trial compared corticosteroids with placebo. One RCT as-
sessed the efficacy of corticosteroids versus no treatment (Dyck
1982). Two trials compared two corticosteroid regimens (Eftimov
2012; Van Schaik 2010). Three completed trials compared corti-
costeroids with IVIg; the CSR of IVIg (Eftimov 2013) includes
the two published trials (Hughes 2001; Nobile-Orazio 2012), and
we have described a trial presented in only abstract form, which
has not been fully published, in the Discussion section of this
overview (Camdessanché 2014).
Corticosteroids versus no treatment
Dyck 1982 compared corticosteroids to no treatment (not
placebo). The trial recruited 40 participants, but five were with-
drawn because of misdiagnosis. Participants were alternately as-
signed to prednisone or no treatment. In the prednisone group, the
dose started at 120 mg every other day and tapered to 0 mg by the
end of 12 weeks. Seven participants (five in the treatment group
and two in the control group) did not complete the study. Of the
five people assigned to prednisone who were excluded, one died
from cardiac arrhythmia, attributed possibly to hyperglycaemia,
three had their prednisone dosage altered from that allowed by the
schedule, and one remained respirator-bound and did not com-
plete follow-up. Referring physicians started two participants in
the untreated control group on prednisone because of deteriora-
tion in their neurological status. As there was no placebo group,
participants were not blinded to the intervention, and the report
does not state whether investigators and follow-up assessments
were blinded.
Of the 28 participants completing the trial according to the pro-
tocol, 14 belonged to each group. The participants in the two
groups were well matched for age, sex, initial NeurologyDisability
Score (NDS, now called theNeuropathy Impairment Score,NIS),
muscle strength, cutaneous sensation, nerve conduction values,
and cerebrospinal fluid protein. The prednisone group included
seven participants with a progressive course and seven participants
with a relapsing course. The untreated group comprised 12 par-
ticipants with a progressive course and two participants with a re-
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lapsing course. Data for the preferred primary outcome measure
for this overview, change in disability after 12 months, were not
available, but we had data for one of our secondary outcome mea-
sures, change in impairment after three months. The conclusions
are sensitive to whether the analysis includes the participants who
did not complete the trial. The trial authors omitted the seven
participants who breached their protocol, and reported results for
the remainder. In this analysis, after 12 weeks the median change
in the NIS (scale range 0 healthy to 280 maximally impaired) was
a worsening of 1.5 points in the untreated group and an improve-
ment of 10 points in the prednisone group, which was a significant
difference between the groups (P = 0.016). The CSR authors re-
calculated the results imputing the worst value for each group for
themissing values, whereupon the results still favoured prednisone
treatment (median change of 2 points worsening in the untreated
group and 5 points improvement in the prednisone group), but
the difference was not statistically significant. The trial authors’
analysis is likely to exaggerate the treatment effect, whilst that of
the CSR authors is likely to be conservative. Ideally a technique
using more balanced assumptions than either of these approaches,
such as multiple imputation or analysis with mixed models, or
both, should be used, but this was not possible, as the CSR authors
did not have access to individual participant data.
The CSR authors also compared the proportions of participants
who improved in impairment, stayed the same, or worsened after
12 weeks. They categorised seven participants who did not com-
plete the trial and were withdrawn as having not improved. With
this imputation, the risk ratio (RR) for improvement was 2.02
(95% confidence interval (CI) 0.90 to 4.52) greater with pred-
nisone than no treatment but the result was imprecise, with CI
that included the possibility of little or no difference. The trial did
not report adverse events in detail but one participant randomised
to corticosteroids died and another developed hyperglycaemia and
was withdrawn.
The CSR authors considered that this one trial provided only very
low-quality evidence about the efficacy of daily oral prednisone
compared with no treatment, and that the trial had a high risk
of bias due lack of allocation concealment, lack of blinding, and
the absence of an intention-to-treat analysis. It was not possible
to comment on a possible increase in harms. The weakness of
the evidence does not necessarily mean that corticosteroids are
ineffective and, as explained in the Discussion, corticosteroids are
widely used.
Comparison of daily standard dose with high-dose monthly
corticosteroids
One parallel-group, double-blind RCT (the PREDICT trial) ran-
domised 41 participants between two different corticosteroid reg-
imens (Van Schaik 2010). One group received a standard oral
prednisolone regimen for 32 weeks, starting with 60 mg daily for
five weeks and then gradually tapering to zero by week 32. The
other group received high-dose monthly oral dexamethasone for
six months, given as 40 mg daily for four days followed by placebo
for 24 days. The primary outcome defined by the trial authors
was reaching and remaining in remission without treatment at 12
months. Remission was defined as a minimum three-point im-
provement on the RivermeadMobility Index and aminimumone-
point improvement in the Inflammatory Neuropathy Cause and
Treatment (INCAT) disability scale. If a participant did not show
improvement or disease stabilisation compared with baseline at
eight weeks, relapsed, or had serious side-effects, trial treatment
was stopped and the participant was considered a treatment fail-
ure. The CSR authors felt that this trial had a low risk of bias be-
cause of randomisation, careful allocation concealment, and iden-
tical appearance of medication in both groups.
Twenty-four participants were assigned to dexamethasone and 16
to prednisolone. The dexamethasone and prednisolone groups
were reasonably matched at baseline. Ten out of 24 participants
in the dexamethasone group and 6 out of 16 participants in the
prednisolone group achieved the trial authors’ primary outcome,
remission at the end of one year, a difference which was not signif-
icant (RR 1.11; 95% CI 0.50 to 2.45). Seven of 24 participants in
the dexamethasone and 8 of 16 participants in the prednisolone
group deteriorated. The CSR authors felt this provided moderate-
quality evidence that there was no significant difference in im-
provement in disability after one year. There were also no signifi-
cant differences between the groups in change inMedical Research
Council (MRC) sum score, grip strength, INCAT disability scale,
INCAT sensory sum score, or Short Form-36 (SF-36) Health Sur-
vey scores. Improvement was somewhat faster in the dexametha-
sone-treated group. Median time to remission was 20 weeks (95%
CI 12.4 to 27.6) in the dexamethasone group in comparison to
39 weeks (95% CI 29.9 to 48.1) in the prednisolone group (P =
0.057). Adverse effects including diabetes mellitus, hypertension,
weight gain, and osteopenia were not significantly different be-
tween oral prednisolone and monthly dexamethasone with the ex-
ception of sleeplessness and cushingoid facies, which were signifi-
cantly more common in the prednisolone group. One participant
in the dexamethasone group developed acute glaucoma after one
cycle and stopped treatment.
Plasma exchange
The updated CSR of plasma exchange (Mehndiratta 2015) iden-
tified two RCTs. The trials compared the short-term efficacy (at 3
weeks and 4 weeks) of plasma exchange and sham exchange (Dyck
1986; Hahn 1996). Neither trial addressed the one-year disability
outcomes preferred for this overview. The review authors judged
both studies to be high quality and at low risk of bias, but the
sample sizes were small. Mehndiratta 2015 did not include a RCT
of plasma exchange for CIDP in participants with IgG and IgA
paraproteinaemic neuropathy, but the updated CSR of treatments
for paraproteinaemic neuropathy (Stork 2015) includes this trial.
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Plasma exchange versus sham exchange
Dyck 1986 was a parallel-group trial with 29 participants that
compared twice-weekly plasma exchange administered for three
weeks to a similar course of sham exchange. Hahn 1996a was a
multicentre cross-over trial that compared 10 plasma exchanges
with a similar number of sham exchanges delivered over four
weeks, with an intended washout period of five weeks. Fifteen
participants completed the trial. The outcome measures were dis-
ability associated. Change in impairment was measured with the
NIS after three weeks in Dyck 1986 and after four weeks in Hahn
1996a. OnlyHahn 1996a measured change in disability. The scale
used was a novel, simple, but unvalidated ad hoc 11-point disabil-
ity scale. Four weeks after treatment, there was a mean of 2 points
(95% CI 0.8 to 3.0 points) more improvement after plasma ex-
change than after sham exchange. The CSR concluded that, com-
pared to sham exchange, there was moderate-quality evidence that
plasma exchange produces short-term improvement in disability
and high-quality evidence of improvement in signs of disease as
measured by a neurologist (Mehndiratta 2015).
With regard to adverse events, the CSR included non-randomised
evidence and concluded that plasma exchange causes adverse
events in 3% to 17% of participants (Mehndiratta 2015). Most
events were mild, such as hypocalcaemia arising from citrate toxi-
city, and hypotension. In an open follow-up study (Hahn 1996a),
one participant had a myocardial infarction while connected to
the cell separator; the relationship to the procedure was uncer-
tain. The CSR also discussed costs and noted that, although costly,
plasma exchange is less expensive than IVIg inmost countries. The
CSR also noted that an expert panel of the European Federation
of Neurological Societies (EFNS) and Peripheral Nerve Society
(PNS) gave its highest level of recommendation to the statement
that if IVIg and corticosteroids are ineffective, plasma exchange
should be considered for treating CIDP (Van den Bergh 2010).
Dyck 1991, which was a trial of plasma exchange versus sham
exchange in IgG and IgA paraproteinaemic neuropathy, reported
a statistically significant improvement in the weakness component
of the NIS, but the updated CSR of paraproteinaemic neuropathy
treatments considered this evidence to be of low quality (Stork
2015).
Intravenous immunoglobulin
The Eftimov 2013 review of IVIg treatment identified eight RCTs
with a total of 332 participants (Vermeulen 1993; Dyck 1994;
Hahn 1996; Thompson 1996; Mendell 2001; Hughes 2001;
Hughes 2008; Nobile-Orazio 2012). Five studies compared IVIg
with placebo, one study compared IVIg with plasma exchange
(Dyck 1994), and two studies compared IVIg with corticosteroids
(Hughes 2001; Nobile-Orazio 2012). We identified another trial,
which was completed but published only in abstract form, that
compared IVIg with corticosteroids (Camdessanché 2014). The
primary outcome in these studies was clinically significant im-
provement in disability (as determined and defined by the trial
authors) within six weeks of onset of treatment.
Intravenous immunoglobulin versus placebo
Three of the five RCTs comparing IVIg with placebo had a paral-
lel-group design (Vermeulen 1993;Mendell 2001; Hughes 2008),
and two had a cross-over design (Hahn 1996; Thompson 1996).
Each trial used a total dose of 2 g/kg IVIg administered over two
days (Mendell 2001), two to four days (Hughes 2008), or five days
(Vermeulen 1993; Hahn 1996; Thompson 1996). In one trial, a
maintenance dose of 1 g/kg every three weeks followed a loading
dose of 2 g/kg (Hughes 2008). Each study used different outcome
measures. The largest study was a randomised, response-condi-
tional cross-over design trial with 117 participants (Hughes 2008).
Participants in Hughes 2008 who did not achieve improvement
with the randomly-allocated treatment after six weeks received the
alternate treatment. After 24 weeks, only participants who im-
proved were rerandomised for an extension period of another 24
weeks. The CSR included the first treatment period because the
sample entering the extension phase was biased in favour of treat-
ment response (Eftimov 2013).
For the primary outcome, five RCTs summarising the results of
235 participants provided data (Vermeulen 1993; Hahn 1996;
Thompson 1996; Mendell 2001; Hughes 2008). The CSR as-
sessed outcomes on disability scales used in the trials (which dif-
fered between trials) at time points of 14 days (Thompson 1996),
16 to 21 days (Vermeulen 1993), 28 days (Hahn 1996), and 42
days (Mendell 2001; Hughes 2008). The CSR authors obtained
42-day data forHughes 2008. According to high-quality evidence,
at the end of the trials more participants had improved after IVIg
(78 out of 141; 53%) than after placebo (30 out of 28; 23%),
with an RR of 2.40 (95% CI 1.72 to 3.36). The number needed
to treat for an additional beneficial outcome was 3.03 (95% CI
2.33 to 4.55).
Only one trial had a longer follow-up; this trial assessed disability
in the 117 participants on the adjusted INCAT disability score at
24 weeks (Hughes 2008). Mean improvement from baseline dis-
ability was 1.1 (SD 1.8) with IVIg and 0.3 (SD 1.3) with placebo;
which was a mean difference of 0.8 (95% CI 0.23 to 1.37). In an
alternative analysis, 45 of the 58 participants assigned to placebo
did not improve one disability grade at 24weeks andwere switched
to IVIg. By contrast, fewer participants (23 of 59) assigned to IVIg
did not respond and were switched to placebo (RR 0.50, 95% CI
0.35 to 0.71).
Adverse events, such as headache, nausea, chills, and fever, were
more common with IVIg than with placebo in the trials included
in the CSR. According to evidence that the CSR authors did not
grade, but which we graded for this overview as of high quality,
a higher proportion of people experienced adverse effects with
IVIg (82 out of 167; 49%) than with placebo (25 out of 141;
18%), which produced a RR of 2.62 (95% CI 1.81 to 3.78).
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The number needed to treat for an additional harmful outcome
(any adverse event) with IVIg was 3.3 (95% CI 2.56 to 4.76).
According to evidence that the CSR assessed as high quality, but
which we consider moderate quality because of imprecision (N =
315), the risk of serious adverse events was 7% with IVIg and 8%
with placebo (RR 0.82, 95% CI 0.36 to 1.87) (Vermeulen 1993;
Mendell 2001; Hughes 2008).
Intravenous immunoglobulin versus corticosteroids
One cross-over trial compared IVIg with prednisolone (Hughes
2001). The CSR authors considered the first treatment period
only and did not grade the quality of the evidence, although they
considered that the trial had a low risk of bias. At four weeks,
nine of 16 participants who received IVIg and eight of 13 par-
ticipants who received prednisolone improved by one point on
the INCAT disability scale. The RR was 0.91 (95% CI 0.50 to
1.68), in favour of IVIg but with CIs that included effects in either
direction. There were also no clear differences in any other effi-
cacy outcomes measured, including the modified Rankin disabil-
ity score and MRC sum score. Serious adverse events occurred in
one IVIg-treated and two prednisolone-treated participants; the
result favoured IVIg but CIs included the possibility of little or no
difference between the groups (RR 0.45, 95% CI 0.04 to 4.69).
One parallel-group, blinded trial compared IVIg 2 g/kg with in-
travenous methylprednisolone 2 g, each given every four weeks
for 24 weeks (Nobile-Orazio 2012). The CSR authors considered
that this trial provided high-quality evidence. The trialists’ own
primary outcome was discontinuation of the randomised medi-
cation, which occurred in three of 24 participants (13%) in the
IVIg group and 11 of 21 participants (52%) in the intravenous
methylprednisolone group, which represented a significant differ-
ence in favour of IVIg (RR 0.54, 95% CI 0.34 to 0.87). How-
ever, according to its protocol, the preselected primary outcome
in the CSR was improvement after two weeks of one grade or
more on the scale used by the trial authors, in this case the Overall
Neuropathy Limitations Scale (ONLS). This outcome occurred
in five out of 24 participants who received IVIg and three out
of 21 participants who received intravenous methylprednisolone;
the result was imprecise and CI allowed for an effect in favour of
IVIg and little or no difference (RR 1.46, 95% CI 0.4 to 5.38).
The CSR also found little or no difference in mean changes in
disability or strength after two weeks. Conclusions about longer-
term outcomes were confounded by the switching of non-respon-
ders to the alternative treatment. Six months after stopping treat-
ment, relapse had occurred in none of the 10 participants who
had responded to intravenous methylprednisolone and eight of
21 participants (38%) who had responded to IVIg, which was a
statistically significant difference (P = 0.032, Fisher’s exact test).
Serious adverse events occurred in two of the 24 participants who
received IVIg and none of the 21 participants who received intra-
venous methylprednisolone.
One open randomised trial compared IVIg, 2 g/kg monthly for
six months, with a course of oral prednisone, 0.8 mg/kg daily
tapered over six months (Camdessanché 2014). The trial results
were published only in abstract form, and thus were not included
in the Eftimov 2013 CSR. After three months, improvement by 1
INCAT grade occurred in 14 of 18 participants who received IVIg
and eight of 17 participants who received prednisone (RR 1.65,
95% CI 0.94 to 2.90). Serious adverse events occurred in three
participants who received IVIg and no participants who received
prednisone (RR 6.63, 95% CI 0.37 to 199.59).
Intravenous immunoglobulin versus plasma exchange
One trial compared IVIg with plasma exchange using an observer-
blind, cross-over design (Dyck 1994). Plasma exchange was per-
formed twice weekly for three weeks and then weekly for three
weeks. Participants received IVIg once weekly at 0.4 g/kg for three
weeks and then 0.2 g/kg weekly for three weeks. The trial ran-
domised 20 participants; one withdrew, and of the 19 who took
part, 13 completed the IVIg and plasma exchange periods, four
completed only the plasma exchange period, and two completed
only the IVIg period. There were no disability outcomes and no
long-term assessments. Unfortunately, neither the analysis nor the
reporting of the study results were ideal because the trial authors
primarily contrasted within-period changes (values at the end of
each period minus those at the start), an approach that has been
criticised because it is not themost statistically powerful way to es-
timate treatment effects. Here, such comparisons were not statisti-
cally significant; there were similar, large improvements frombase-
line in the NIS with both treatments after six weeks: mean (SD)
38.3 points (34.6) after plasma exchange and mean 36.1 points
(32.0) after IVIg. The standardised mean difference between the
two treatments was not significant, -0.06 points (95% CI -0.76 to
0.63). The small size of this difference and wide CI suggest that
the differences between the two treatments would still not have
been statistically significant had a more statistically powerful anal-
ysis been used. Another concern about this study is that there were
many dropouts, which might have resulted in bias. Furthermore,
these analyses may have been biased by the differences at baseline
between the participants who took part in each treatment period.
The authors of the Eftimov 2013 CSR considered that this trial
provided moderate-quality evidence of no significant difference in
short-term efficacy between the two treatments.
In the plasma exchange period of this study, “a few” participants
required indwelling venous catheters. Minor side-effects such as
light headedness, nausea, and rash were “quite common”. No se-
rious complications were recorded during the IVIg treatment pe-
riods. Neither we nor the Eftimov 2013 CSR authors are able to
comment on the quality of the evidence for the relative frequency
of adverse events, because of lack of information.
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Azathioprine
There has only been one randomised trial of azathioprine (Dyck
1985). This open-label, parallel-group trial in adults had a high
risk of bias. It compared nine months’ treatment with a combi-
nation of azathioprine 2 mg/kg and prednisone with prednisone
alone. Both groups started at 120 mg prednisone every other day,
tapered over nine months. Follow-up data were available for 13
of 14 participants in the azathioprine and prednisone group and
10 of 13 participants in the prednisone alone group. The trial au-
thors did not collect measures of disability desired for the CSR
(Mahdi-Rogers 2013) and this overview. After nine months, there
was a median improvement of 29 points on the Mayo Clinic NIS
(range 49 points worse to 84 points better) in the participants who
received azathioprine and prednisone, compared with a worsening
of 30 points (range 20 points worse to 104 points better) in the
prednisone alone group. This difference was not statistically sig-
nificant, nor were the changes in any of the other clinical measures
of impairment or nerve conduction collected by the authors sta-
tistically significant. The CSR authors did not grade the evidence
quality but we consider it to be very low because of imprecision,
a single small study, and lack of blinding.
Methotrexate
One parallel-group trial with a low risk of bias tested the efficacy of
low-dose oral methotrexate, a well-tolerated immunosuppressant
often used in rheumatoid arthritis (RMC 2009). It randomised
60 adults with CIDP with or without paraprotein (but not anti-
myelin-associated-glycoprotein antibodies) to methotrexate (7.5
mg weekly for four weeks, then 10 mg weekly for four weeks,
then 15 mg weekly for 32 weeks) or placebo. Both groups received
folic acid 5 mg twice weekly as is usually coadministered with
methotrexate to prevent mouth ulcers and gastrointestinal side-ef-
fects. The primary outcome for the Mahdi-Rogers 2013 CSR and
this overview, change in disability after one year, was not available
because follow-up ended after 40 weeks. All participants were re-
quired to have been receiving corticosteroids, IVIg, or both at the
start of the trial. After 16 weeks, the dose of IVIg or corticosteroids
was reduced by 20% of the starting dose every four weeks. The
trial used the ONLS to measure disability (Graham 2006), which
is very similar to the INCAT scale. If participants worsened by one
grade, the original IVIg or corticosteroid dose was restarted. The
primary outcome was the reduction in corticosteroid or IVIg dose
in weeks 37 to 40 compared with weeks one to four. Response was
defined as reduction of corticosteroid or IVIg dose by more than
20%. Fourteen of 27 participants (52%) were responders in the
methotrexate group and 14 of 32 were responders in the placebo
group (44%), adjusted odds ratio 1.21 (95%CI 0.40 to 3.70). The
CSR authors graded this as low-quality evidence that methotrex-
ate did not allow more participants to reduce their corticosteroid
or IVIg dose by 20% than did placebo.
The closest outcome measure to the primary outcome for the CSR
and this overview was change in disability after 40 weeks. This
was measured in two ways and the results were not significant
with either. The first method compared the median changes from
baseline in theONLS; thesewere similar in themethotrexate group
0 (interquartile range (IQR) -1 to 0) and the placebo group 0 (IQR
-0.75 to 0). The secondmethod compared themean (SD) changes
frombaseline of another disabilitymeasure, the AmsterdamLinear
Disability score, in which the change in the methotrexate group
was -0.66 (4.25) and in the placebo group -0.48 (2.40). The mean
change from the baseline of the AmsterdamLinear Disability score
of themethotrexate groupwas -0.47points (95%CI -3.62 to 1.87)
less than that of the placebo group, with adjustment for baseline
score, baseline IVIg or corticosteroid dose per week per kg, and
age. These changes in disability were not significant and in any
case might have been affected by alterations in the corticosteroid
or IVIg doses required by the protocol.
Serious adverse events occurred in three participants in the
methotrexate group and one participant in the placebo group, RR
3.56 (95 % CI 0.39 to 32.23).
Interferon beta-1a
There have been two RCTs of interferon beta-1a (IFN beta-1a).
Hadden 1999 performed a placebo-controlled cross-over trial in
treatment-resistant CIDPwith treatment periods of only 12 weeks
and a four-week washout period. The dose was low: IFN beta-1a
11 µg thrice weekly for two weeks then 22 µg thrice weekly for
10 weeks. The primary outcome for the CSR and this overview
was not available, but change in disability 12 weeks after start of
treatment was reported. The median within-period improvement
in the Guy’s Neurological Disability Scale (similar to the INCAT
scale) was very similar in the two treatment periods, 0.5 grades
(IQR 1.8 grades better to 0 grade change) in the IFN beta-1a treat-
ment period and 0.5 grades (IQR 1.8 grades better to 1.0 grade
worse) in the placebo treatment period. As noted above, compari-
son of within-period changes between treatment groups is not an
ideal method of analysis for cross-over trials. Nonetheless the fact
that these changes are so similar in the two treatment groups sug-
gests that a more statistically powerful approach would have been
unlikely to yield significant results. There were no serious adverse
events during either treatment period.
Hughes 2010 conducted a placebo-controlled, parallel group trial
of intramuscular IFN beta-1a or matching placebo given in one
of four doses: 30 µg once weekly, 60 µg once weekly, 30 µg twice
weekly, or 60 µg twice weekly for 32 weeks. This trial used the
OverallDisability Sum Score (ODSS), which is almost identical to
the ONLS (Graham 2006). After 16 weeks, IVIg was stopped and
then restarted if the participant worsened by 1 point on theODSS
and 2 points on the MRC sum score. The trial authors’ primary
outcome was the total IVIg dose administered in weeks 16 to 32.
This was not significantly different between all the IFN beta-1a
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groups combined (1.20 g/kg) and the placebo group (1.34 g/kg) (P
= 0.75). The CSR authors concluded that Hughes 2010 provided
moderate-quality evidence of no significant difference between
IFN beta-1a and placebo in the risk of not restarting IVIg after the
withdrawal phase (47% in both groups). There was high-quality
evidence that serious adverse events were not significantly more
common with IFN beta-1a, although there were adverse events
in four participants in the IFN beta-1a group and none in the
placebo group, RR 4.50 (95 % CI 0.25 to 80.05). The outcomes
desired for the CSR and this overview were not available, except
for serious adverse events.
Other pharmacological agents and
immunosuppressive regimens
There have been no RCTs of other immunosuppressive or im-
munomodulatory agents. A parallel-group trial of oral fingolimod
0.5 mg daily versus placebo started in 2013, but participant re-
cruitment was halted in 2016 because of futility (FORCIDP 2013;
Hartung 2014).
Treatment for fatigue
A published CSR for assessing treatment for fatigue in peripheral
neuropathy identified no randomised trials in people with CIDP (
White 2014). Neither the review nor our searches for this overview
identified any RCTs of interventions for fatigue in CIDP.
Treatment for pain
Our search did not reveal any systematic reviews or RCTs of
treatment for pain in CIDP, but there have been multiple high-
quality trials and several CSRs of treatment for neuropathic pain
caused by polyneuropathy and herpes zoster (postherpetic neural-
gia) (Hempenstall 2005).
D I S C U S S I O N
Summary of main results
Corticosteroids
The conclusions that can be drawn about the efficacy of corticos-
teroids for chronic inflammatory demyelinating polyradiculoneu-
ropathy (CIDP) are limited because they depend on only two tri-
als (Hughes 2015). It is uncertain whether daily oral prednisone
produces improvement in impairment compared to no treatment,
because the evidence is very low quality. According to moderate-
quality evidence from the other trial, high-dose monthly oral dex-
amethasone for six months probably does not differ significantly
in efficacy from daily oral prednisolone. Both treatments caused
short-term side-effects, but, also according to moderate-quality
evidence, sleeplessness and moon-shaped face were probably less
common with monthly dexamethasone. The paucity of evidence
contrasts with the extensive use of corticosteroids in practice and
their recommendation as a primary treatment option for CIDP in
international guidelines (Van den Bergh 2010).
Plasma exchange versus sham exchange
Two trials of plasma exchange compared with sham exchange for
CIDP provided moderate-quality evidence of more improvement
in disability, and high-quality evidence of more improvement in
impairment with plasma exchange (Mehndiratta 2015). The im-
provements were large and clinically important. Serious adverse
events occurred in two of 52 randomised participants. The review
authors did not comment on the quality of the evidence about
adverse events, but we consider the evidence about adverse events
to be of very low quality because of unclear reporting.
In paraproteinaemic neuropathy, one trial provided some evidence
of more improvement in impairment with plasma exchange than
sham exchange (Dyck 1991). The Stork 2015 Cochrane System-
atic Review (CSR) did not grade the evidence for benefit but we
consider the evidence of low quality because of serious impreci-
sion. There were no data about adverse events for the trial (Dyck
1991).
Intravenous immunoglobulin versus placebo
In the Eftimov 2013 CSR of intravenous immunoglobulin (IVIg)
in CIDP, five trials provided evidence that more participants had
short-term improvement in disability after IVIg (44%) than after
placebo (18%) (risk ratio (RR) 2.40, 95% confidence interval
(CI) 1.72 to 3.36). Adverse events were more common with IVIg
than with placebo. Serious adverse events were probably no more
common with IVIg than with placebo. One trial had a 24-week
extension phase in which responders were rerandomised to IVIg
or placebo (Hughes 2008). Relapses were less common in the
IVIg recipients: specifically, no relapse occurred in 37/43 (86%)
participants in the IVIg group compared with 16/31 (52%) in
the placebo group (absolute risk reduction 34% (95% CI 14 to
55%) and the number needed to treat for an additional beneficial
outcome was 2.94 (95%CI 1.82 to 7.13). The Eftimov 2013 CSR
excluded these results because of potential bias of the extension
period enrichment design that would be expected to exaggerate
the efficacy of IVIg.
Azathioprine
It is uncertain whether the addition of azathioprine (2 mg/kg) to
prednisone improves impairment, as the quality of the evidence is
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very low (1 trial, 27 participants) (Dyck 1985). The trial did not
report adverse events.
Methotrexate
According to low-quality evidence from one trial, there may be
little or no difference between methotrexate and placebo in the
change in disability as measured with either the Overall Neuropa-
thy Limitations Scale (ONLS) or the AmsterdamLinear Disability
score after 40 weeks’ treatment (RMC 2009). There were more
serious adverse events with methotrexate than with placebo.
Interferon beta-1a
One trial of interferon beta-1a (IFN beta-1a) showed little or no
benefit after 12 weeks. According to evidence judged to be of
moderate quality by the Mahdi-Rogers 2013 CSR, the only other
trial of IFN beta-1a found little or no benefit from IFN beta-1a
after 32 weeks. This trial did not identify more serious adverse
events with IFN beta-1a than with placebo, evidence which the
review authors considered high quality but which we considered
only moderate quality because it lacked precision.
Direct comparisons of corticosteroids, plasma
exchange and intravenous immunoglobulin
Intravenous immunoglobulin versus corticosteroids
The evidence directly comparing corticosteroids and IVIg depends
on three RCTs, of which one has not been published in full nor
incorporated in a CSR (Camdessanché 2014). One blinded cross-
over trial comparing IVIg with oral prednisolone had only 32
participants. It did not show a significant difference between the
treatments in either six-week improvement of disability or occur-
rence of serious adverse events (Hughes 2001). A parallel-group,
blinded, six-month trial comparing IVIgwith intravenousmethyl-
prednisolone did not show significant differences in disability af-
ter two weeks, but did show that significantly more participants
responded to IVIg in the short term (Nobile-Orazio 2012). Ac-
cording to unpublished information provided by the trial authors,
an open, six-month, parallel-group trial comparing IVIg with oral
prednisone did not show clear differences in disability after three
months (Camdessanché 2014). However, the CIs include both
no difference between the treatments and a relevant difference.
Although Camdessanché 2014 suggested that treatment response
was more likely with IVIg than intravenous methylprednisolone,
the other two studies did not support this conclusion. All three
studies were small. The discordance of outcomes and treatment
intervals in these three RCTs prevented us combining their re-
sults in a meta-analysis. Thus, the low numbers of participants in
these somewhat heterogeneous trials comparing IVIg with corti-
costeroids make it impossible to draw confident conclusions about
which intervention, if either, is superior. For the same reason, it is
unclear whether the more frequent occurrence of serious adverse
events with IVIg than with corticosteroids in each of these trials
represents a real difference or is coincidental (1/30 with IVIg and
0/27 with prednisolone in Hughes 2001, 2/24 with IVIg and 0/
21 with intravenous methylprednisolone in Nobile-Orazio 2012,
and 3/18 with IVIg and 0/17 with prednisone in Camdessanché
2014). A meta-analysis combining these results gives a RR of 4.56
(95%CI 0.82 to 25.39), indicating more adverse events with IVIg
than with corticosteroids but with very serious imprecision. The
trials did not last long enough to detect the known serious side-
effects of long-term corticosteroid treatment.
A retrospective non-randomised comparison of two groups of peo-
ple with CIDP, one group of 36 who were dependent on mainte-
nance treatment and one group of 34 who were able to withdraw
treatment, found that IVIg was more often effective than cor-
ticosteroids but successful withdrawal from treatment was more
common after corticosteroids than after IVIg (Rabin 2014). This
trial also identified multifocal deficit and a longer delay in starting
treatment as factors associated with treatment dependence. More
prospective, preferably randomised, studies are needed to confirm
these observations.
Intravenous immunoglobulin versus plasma exchange
A single, small cross-over trial showed no significant difference in
change in impairment after six weeks between IVIg and plasma
exchange (Dyck 1994). The CSR assessed this as moderate-quality
evidence (Eftimov 2013).
Corticosteroids versus plasma exchange
There have been no direct comparisons of corticosteroids with
plasma exchange.
Indirect comparisons of corticosteroids, plasma
exchange and intravenous immunoglobulin
Indirect comparisons of corticosteroids, IVIg, and plasma ex-
change with network analysis were not possible because of differ-
ing outcome measures and times of data collection between tri-
als. Limited conclusions about the comparison of the short-term
efficacy of corticosteroids versus IVIg, and IVIg versus plasma
exchange can be drawn from the small direct comparative trials
cited above. With regard to the comparison of corticosteroids and
plasma exchange, there is some relevant information: in the Dyck
1982 trial there was a median improvement of 5 NIS points after
12 weeks of prednisone treatment, compared with a median wors-
ening of 2 NIS points with no treatment, and in the Mehndiratta
2015 CSRmeta-analysis of the two plasma exchange trials, a mean
improvement in NIS of 30.6 points (95% CI 44.72 to 16.49)
more after three or four weeks of plasma exchange than after sham
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exchange (Mehndiratta 2015). Although the differences in treat-
ment times and participant characteristics precluded formal net-
work analysis, the 24-point greater improvement with plasma ex-
change than with corticosteroids could suggest that plasma ex-
change has greater short-term efficacy.
Other immunosuppressive or immunomodulatory
regimens
Neither the Mahdi-Rogers 2013 CSR, nor the search conducted
for this overview identified any completed RCTs of other im-
munosuppressive or immunomodulatory agents or regimens other
than those described above. The CSR described observational
studies of other immunosuppressive regimes in its discussion.
These included alemtuzumab, cyclophosphamide, ciclosporin, in-
terferon alfa, mycophenolate, natalizumab, rituximab, tacrolimus,
and bone marrow stem cell transplantation. None of the studies
was so convincing as to avoid the need for RCTs to establish the
balance between benefit and harm for these regimens. Reports that
treatment with some of these agents for other conditions has been
associated with the onset of inflammatory neuropathy, as noted
by the CSR, are concerning. A parallel-group trial of oral im-
munosuppressant drug fingolimod 0.5 mg daily started in 2013,
but participant recruitment was halted in 2016 because of futility
(FORCIDP 2013; Hartung 2014). Despite the absence of evi-
dence from RCTs, immunosuppressant regimes, such as azathio-
prine, mycophenolate, and cyclophosphamide, are often used in
clinical practice in people with CIDP who are either resistant to
first-line treatments, or in whom side-effects, cost, or inconve-
nience of first-line treatments become problematic (Cocito 2010).
Adverse events
All the treatments considered in this overview carry the risk of
side-effects, which the available reviews of predominantly short-
term trials have not captured adequately. The 12-week trial of oral
prednisolone did not give details of adverse events. Monthly dex-
amethasone treatment for six months caused short-term side-ef-
fects with a similar frequency to daily oral prednisolone, but sleep-
lessness and moon facies were less common with dexamethasone
(moderate-quality evidence). Corticosteroids are known from ob-
servational studies to carry a long-term risk of serious side-effects.
IVIg caused significantlymore adverse events thanplacebo. Serious
adverse events were not significantly more common; however, the
sample size was small for quantification of serious adverse events.
Serious side-effects have occurred in observational studies.
Serious adverse events occurred in the plasma exchange versus
sham exchange trials. Observational studies have reported adverse
events related to difficulty with venous access, use of citrate, and
haemodynamic changes.
The trial of azathioprine did not report adverse events. In the in-
cluded review, serious adverse events were not more frequent with
IFN beta-1a or methotrexate than with placebo. Serious side-ef-
fects have occurred, especially with azathioprine and methotrex-
ate, in observational studies.
Factors affecting the choice of treatment
Despite the lack of high-quality evidence for the efficacy of corti-
costeroids from randomised trials, use of oral corticosteroid regi-
mens will continue because of favourable empirical clinical effec-
tiveness, global availability, familiarity of neurologists with their
use, convenience of administration, and low cost. Against this, the
serious and potentially costly adverse effects of long-term use must
be considered.
There is more published evidence for the efficacy of IVIg than
for corticosteroids or plasma exchange. IVIg is both less available
and less convenient than corticosteroids, but more available and
convenient than plasma exchange. IVIg has a different adverse
effect profile to corticosteroids, but is not free of adverse events.
In the non-randomised literature, mild transient adverse effects
occurred in 1% to 15% of IVIg infusions (Duhem 1994; Stiehm
1996). In a parallel-group RCT involving 27 participants, there
was no significant difference in efficacy or side-effect profile of
two different brands of IVIg (Kuitwaard 2010). In a retrospective
review of 244 people with neurological conditions, of whom the
majority were older than 60 years, the rate of adverse effects with
IVIg was 35% (Lozeron 2016). Most of these adverse effects were
transient hypertension and headache, but acute renal dysfunction
and venous thrombosis occurred in 2%. Other severe side-effects,
including generalised erythematous skin reactions (Hurelbrink
2013), anaphylactic shock, haemolytic anaemia, and stroke seem
to be uncommon, occurring in fewer than 0.5% of more than
26,000 infusions in a post-marketing clinical pharmacovigilance
study (Martin 2000). One of the disadvantages of IVIg is the
inconvenience and expense of attending hospital for the infusions,
which last for several hours. This is increasingly mitigated by at-
home administration where this is possible (Katzberg 2013).
Subcutaneous immunoglobulin could be a more convenient alter-
native to IVIg if it were as effective, particularly as the treatments
can be administered at home. The Markvardsen 2013 RCT, in-
volving 29 participants, has not yet been included in a CSR, but it
showed that subcutaneous immunoglobulin produced more im-
provement in strength thanplacebo.Twenty of 29participants said
that they preferred subcutaneous to intravenous immunoglobu-
lin. A recent meta-analysis concluded that subcutaneous and in-
travenous immunoglobulin are equally effective in CIDP and in
multifocal motor neuropathy (Racosta 2016). The ongoing Van
Schaik 2016 RCT is also investigating the efficacy of subcutaneous
immunoglobulin and the next updates of Eftimov 2013 and this
overview will include this trial.
The fact that there is more evidence for the efficacy of IVIg mainly
reflects that more studies have been conducted. This is through
industry support and the necessity for licensing and does not mean
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that IVIg is more effective than other treatments. As noted above,
the trials comparing IVIg with corticosteroids did not show a
significant difference in short-term efficacy.
There is probably little or no difference in short-term efficacy be-
tween plasma exchange and IVIg. Inconvenience and discomfort,
the requirement for hospital attendance and specially trained staff,
and the risk of side-effects limit the use of plasma exchange. In a
series of 381 plasma exchange procedures for various indications,
complications, usually from the use of a central venous catheter,
occurred in 17% of 381 procedures. These events included two
deaths, one from arterial haemorrhage caused by the insertion of
a central venous catheter, and one from the underlying disease
(Couriel 1994). In a larger series, complications occurred in 3.9%
of 17,940 procedures on 3583 people and included citrate toxicity
(3%), vasovagal reactions, vascular access complications, cardiac
arrhythmia, haemolysis, hepatitis B, and fresh frozen plasma reac-
tions, but no treatment-related deaths (Kiprov 2001).
Overall completeness and applicability of
evidence
The evidence included in this overview covers all the randomised
trials of treatments for CIDP that we found, except for six trials
that are awaiting incorporation into individual CSRs. One trial of
lipoic acid has been completed according to the ClinicalTrials.gov
entry but the contact has not answered our request for the results
(NCT00962429). Another trial, of 3,4-diaminopyridine, a drug
hoped to improve conduction in partly demyelinated nerve fibres,
showed no significant benefit on any measure of impairment. This
trial has not been included in any CSR because it has not fallen
within their inclusion criteria, and a title will be registered for it and
similar agents. The study had a blinded cross-over design, included
34 stable participants and used only four days of treatment (Russell
1995). There have been no other trials of this drug in CIDP, but
trials of a similar drug, 4-aminopyridine, showed an improvement
inwalking speed inmultiple sclerosis and resulted in its registration
for that indication by the Food and Drugs Administration in the
USA (Goodman 2009). In a third trial, Hu 2009 tested Guilong
Tongluo Capsule in 60 people with CIDP. Half of the participants
received the capsule and prednisone, and half of them received
prednisone alone. After three months, the “total effective rate” on
a variety of measures was 90.0% (27/30) with Guilong Tongluo
Capsule and 70.0% (21/30) without the intervention, which is
not statistically significant (Fisher’s exact test P = 0.104), despite
the trial authors’ claim to the contrary.
Corticosteroids
The conclusion of theHughes 2015 CSR that the one randomised
trial of oral corticosteroids did not show a statistically significant
benefit over no treatment appears to be at odds with clinical expe-
rience. However, the quality of the evidence from the randomised
study was very low; with a high risk of bias and imprecise results
that allowed for large effects in favour of corticosteroids and little
or no difference. Following current Cochrane practice, which re-
ports findings in terms of the quality of evidence rather than their
statistical significance, we have stated the effect of corticosteroids
in this trial to be uncertain because of the very low-quality evi-
dence. In the absence of more evidence from RCTs, the Hughes
2015 CSR considered the evidence from observational studies.
These uniformly reported the apparent efficacy of corticosteroids.
The largest and most helpful, albeit retrospective, study, included
136 participants from Italy treated with corticosteroids as first-line
therapy; 51% responded with a one or more point improvement
in the Rankin disability score, and 12.5% had adverse effects (five
had diabetes mellitus, four hypertension, three osteoporosis, three
duodenal ulcer, two psychosis, and one obesity) (Cocito 2010).
Fourteen participants who had previously been treated with IVIg
were switched to corticosteroids, and six participants (43%) re-
sponded. This very low-quality evidence suggests that corticos-
teroids can induce at least short-term improvement in about half
of people with CIDP. The Cocito 2010 study also documented
the improvement of some people on corticosteroids after switch-
ing from IVIg.
Intravenous immunoglobulin and plasma exchange
There is at least moderate-quality evidence included in this
overview supporting the short-term efficacy of IVIg and plasma
exchange, but the evidence is limited by the small numbers of tri-
als, the low numbers of participants and by the short duration of
follow-up, which was in many cases limited to four to six weeks.
We considered evidence from one trial suggesting efficacy of IVIg
for as long as 24 weeks to be potentially biased by exclusion of
non-responders from randomisation. Clinical experience suggests
that benefit from regular IVIg or plasma exchange treatments can
last beyond six months, although trials have not so far investigated
longer-term effects. Most trials reported adverse events; however,
longer-term follow-up is also necessary to capture adverse events
adequately and we have indicated observational studies reporting
these.
Azathioprine, methotrexate, and interferon beta-1a
Based on evidence from single trials, it is uncertain whether aza-
thioprine is of benefit in CIDP, and methotrexate may have no
clear benefit. Two trials of IFN beta-1a for CIDP provided mod-
erate quality evidence of no significant benefit. This evidence is
limited by the small size of the trials and the low doses used: only
2.0 mg/kg daily of azathioprine (maximum dose 2.5 mg/kg daily)
(Dyck 1985) and 15 mg weekly of methotrexate (RMC 2009).
The doses of IFNbeta-1a ranged from very low, 30 µg once weekly,
to very high, 60 µg twice weekly (Hughes 2010).
The trial of azathioprine only lasted for nine months, whereas in
a similar trial in myasthenia gravis a treatment effect did not be-
18Treatments for chronic inflammatory demyelinating polyradiculoneuropathy (CIDP): an overview of systematic reviews (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
come evident until after 12 months (Palace 1998), so it would be
premature to draw conclusions about the efficacy of azathioprine
from this trial alone. The CSR summarised results from published
case series in which 28 of 88, about one third of participants, were
reported to have benefited (Mahdi-Rogers 2013). Thus the qual-
ity of the evidence from the trial and from observational studies is
very low and inadequate to establish whether azathioprine is bene-
ficial in CIDP. Furthermore, although the trial did not report side-
effects, in observational studies azathioprine is known to cause
nausea, vomiting, diarrhoea, and allergic reactions, including rash,
which prevent its continuation in about 10% of people. Azathio-
prine also causes leucopenia, altered liver function, and increased
susceptibility to infection (Confavreux 1996; Kissel 1986). There
is a theoretical risk of neoplasia but a large retrospective cohort
study of immunosuppressive agents in autoimmune ocular disease
did not show an actual increased incidence in people treated with
antimetabolites such as azathioprine, methotrexate, andmycophe-
nolate mofetil after 17,316 person-years (Kempen 2009).
The evidence concerning methotrexate was limited by the unex-
pectedly high proportion of responders in the placebo group and
the subjective component in the dose adjustment on which the
primary outcome depended. There is little information about ben-
efit from observational studies: the CSR identified published re-
ports of benefit in about one-third of people (8 of 23) with CIDP
who were treated with the drug (Mahdi-Rogers 2013). Side-effects
of methotrexate are well recognised. However, in a retrospective
review of 248 people with rheumatoid arthritis on a mean dose
of methotrexate 12.6 mg at the last visit, only 0.8% stopped tak-
ing methotrexate because of laboratory abnormalities and 10%
because of side-effects (Yazici 2005).
Neither trial of IFN beta-1a included in the CSR showed clear
benefit. Although apparent benefit was reported in 15 of 34 par-
ticipants in case reports and case series identified in the CSR, such
evidence is highly susceptible to reporting bias and this method
of treatment has not been pursued. IFNb-1a often causes minor
alterations of liver function and white cell counts and, upon sub-
cutaneous administration, skin reactions, but serious side-effects
are rare (Rice 2001).
Treatment for fatigue
Our search did not reveal any RCTs of treatment for fatigue that
included participants with CIDP.
Treatment for pain
Althoughmany trials and some systematic reviews of treatment for
painful neuropathy exist, our search did not reveal any trials that
randomised participants with CIDP. It is possible but not known
that people with CIDP respond to similar agents, and these are
often used in practice.
Paraproteinaemic neuropathies
it is uncertain whether the evidence summarised here for CIDP
can be applied to people who also have a paraprotein. Parapro-
teins are sometimes associated with CIDP. Paraproteins can be
associated with malignant plasma cell dyscrasias but commonly
there is no current evidence of neoplasia and the paraprotein is
classified as a ”monoclonal gammopathy of undetermined signif-
icance“ (MGUS). At least half of people with IgM paraproteins
have associated antibodies to myelin-associated glycoprotein and
are therefore classified as not having CIDP. Those with IgG or IgA
paraproteins often have a similar clinical course to CIDP with-
out a paraprotein and are classified as having atypical CIDP (Van
den Bergh 2010). Limited evidence from one randomised trial de-
scribed above showed that plasma exchange produced significant
short-term benefit compared with sham exchange (Dyck 1991).
Randomised trials of corticosteroids or IVIg have not been per-
formed specifically in people with this disease variant, but very
small numbers of such people have been participants in some of
the trials included in this overview.
The evidence in this overview is based on RCTs involving adults
withmore or less typical forms of CIDP.Most RCTs excluded chil-
dren, in whom observational studies suggest that IVIg and corti-
costeroids are equally likely to be effective (McMillan 2013). Trials
also excluded the very old, for whom no separate information is
available, and atypical forms of CIDP. Large case series and narra-
tive reviews of the treatment of such people may be informative,
but fall outside the scope of this review. Observational studies have
reported deterioration of pure motor CIDP with corticosteroids
(Donaghy 1994). On this account, corticosteroids are not gener-
ally recommended in this atypical variant (Van den Bergh 2010).
Ayrignac 2013 reported a series of 22 people with pure sensory
CIDP; in 14 of 15 people who received immunotherapy, the treat-
ment was considered effective. Participants in the trials also needed
to be without significant comorbidity, so conclusions may not be
applicable to people who have coexistent diabetes mellitus, which
might be considered a relative contraindication to corticosteroids.
Costs
Economic analyses are difficult to perform and the outcomes
vary depending upon the model used, the variables considered,
the time over which costs are averaged and the healthcare sys-
tem in which the treatment is provided. Corticosteroids, espe-
cially oral prednisolone and dexamethasone, are inexpensive and
these are the cheapest of the three treatments currently recom-
mended by the European Federation of Neurological Societies/Pe-
ripheral Nerve Society (EFNS/PNS) guideline by orders of mag-
nitude (Van den Bergh 2010). For much of the global popula-
tion, these are the only available treatment options. IVIg is the
most expensive: one European study calculated the extra cost of
IVIg compared with corticosteroids per quality-adjusted life year
(QALY) gained as EUR 250,000 (McCrone 2003). A Canadian
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study estimated the incremental cost per QALY gained of IVIg
compared with corticosteroids as CAD 687,287 (approximately
USD 535,800) (Blackhouse 2010). By contrast, based on societal
willingness-to-pay thresholds, a study in Thailand concluded that
IVIg is a cost-effective treatment for corticosteroid-resistant CIDP
(Bamrungsawad 2016). Nevertheless, in many countries IVIg is
not an affordable option, whereas plasma exchange can be a more
available and affordable alternative to corticosteroids. Other im-
munosuppressants have not been shown to offer significant ben-
efit but if they were shown to be effective, older oral treatments
would offer significant cost benefits, in particular when compared
with IVIg.
Quality of the evidence
The methods used in each of the CSRs followed Cochrane stan-
dards and fulfilled the desirable attributes in the Assessing the
MethodologicalQuality of Systematic Reviews (AMSTAR) check-
list (see Table 1).
We consider the small number of trials and participants to be the
major impediment to producing a high-quality review, especially
those addressing the long-term disability outcome desired for this
overview.
Potential biases in the overview process
The overview process is vulnerable to criticism in that some of
the overview authors also authored some of the trials or reviews
included in this overview and had consultancies with some of the
companies producing the drugs being considered (seeDeclarations
of interest). Where judgments about quality were made, two
overview authors who had no commercial conflicts of interest and
who were not authors of included CSRs made assessments inde-
pendently. Additionally, these authors performed an independent
selection of reviews and studies for inclusion.
Agreements and disagreements with other
studies or reviews
There have been no other formal systematic overviews of treat-
ments for CIDP. Other reviews have quoted the relevant CSRs
and reached the same conclusions as this overview, namely that
corticosteroids, plasma exchange and IVIg have significant short-
term efficacy (Fergusson 2005; Donofrio 2009). One systematic
review (Bright 2013) included three trials excluded from our re-
view:
1. A trial of rituximab for anti-myelin-associated glycoprotein-
associated antibody demyelinating neuropathy (Dalakas 2009),
which is generally considered a different entity from CIDP and
which did not fulfil the inclusion criteria for our review.
2. A trial comparing immunoabsorption with IVIg (Zinman
2005), which the Eftimov 2013 review excluded because of low
quality related to loss to follow-up of 10 of the 20 participants at
six months.
3. A trial of IVIg versus placebo in multifocal motor
neuropathy (Léger 2001), which did not fulfil the inclusion
criteria for our review.
In addition, Bright 2013 excluded the trials of plasma exchange
and did not mention the trials comparing IVIg with corticos-
teroids.Despite these differences, Bright 2013 reached similar con-
clusions to ours. An expert panel of the EFNS and PNS considered
that the evidence for short-term efficacy of corticosteroids was of
moderate quality (Class II in their classification), for IVIg of high
quality (Class I), and for plasma exchange of high quality (Class
I) (Van den Bergh 2010). Despite the absence of confirmatory
trials, the same panel recommended combination treatments or
adding an immunosuppressant or immunomodulatory drug for
treatment of resistant disease.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
The available reviews provide evidence of variable quality, mostly
from short-term trials, about the efficacy of different treatments. It
is uncertain from the randomised controlled trial (RCT) evidence
whether daily oral prednisone for 12 weeks produces more im-
provement than no treatment for chronic inflammatory demyeli-
nating polyradiculoneuropathy (CIDP). High-dose monthly oral
dexamethasone for six months probably does not differ signifi-
cantly in efficacy from daily oral prednisolone. Use of corticos-
teroids is widespread, supported by clinical experience and very
low-quality evidence from observational studies.
Intravenous immunoglobulin (IVIg) produced more short-term
(four-week to six-week) improvement in disability than placebo.
There is little or no difference in short-term improvement of dis-
ability with IVIg in comparison with intravenous methylpred-
nisolone, and probably little or no difference in comparison with
oral prednisolone.
Plasma exchange probably produces more short-term improve-
ment in disability than sham exchange. There is probably little
or no difference in short-term improvement in impairment with
plasma exchange compared to IVIg.
At themostly lowdoses tested, it is uncertainwhether azathioprine
is effective, as the evidence is very low quality; methotrexate may
not be effective; and interferon beta-1a is probably not effective.
There are no completed RCTs of other immunosuppressive or
immunomodulatory agents.
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There is not enough evidence overall, and no high-quality evi-
dence, tomake indirect statistical comparisons (across trials) of the
relative efficacy of any of the interventions that have been investi-
gated in RCTs. The collection and reporting of adverse events in
the performed trials is variable. Furthermore, where adverse events
are relatively uncommon and their occurrence too infrequent to
pick up in small trials, the data presented for adverse events from
these trials cannot be used to influence clinical decisions about the
relative safety of one agent over another. Practitioners and peo-
ple with CIDP should consider well-known adverse effects of the
agents from case series and trials in other conditions described in
this overview when making a choice of treatment.
A significant number of heterogeneous agents with potential effi-
cacy in CIDP have not been studied in a high-quality RCT. We
cannot comment on their efficacy and safety in practice in this
overview.
Implications for research
We need further research to compare the risk of side-effects and
long-term benefit from the agents which produce short-term ben-
efit. We need to identify genetic, immunological, or other factors
which predict individual responses to each of the treatments in-
cluding the risk of deterioration following their withdrawal. We
also need to compare the cost-effectiveness of these treatments in
different healthcare settings. Evidence-based consensus concern-
ing outcome measures and time points would assist comparison of
different agents and trials. Testing larger doses of azathioprine or
methotrexate or some of the many other available immunomod-
ulatory agents as initial, secondary, or combination treatments
would be worthwhile. Research should also include treatments for
fatigue and pain in CIDP and investigation of the role of psycho-
logical and social factors in causing disability.
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A D D I T I O N A L T A B L E S
Table 1. AMSTAR* quality criteria for systematic reviews
1. Was an ‘a priori’ design provided?
2. Was there duplicate study selection and data extraction?
3. Was a comprehensive literature search performed?
4. Was the status of publication (i.e. grey literature) used as an inclusion criterion?
5. Was a list of studies (included and excluded) provided?
6. Were the characteristics of the included studies provided?
7. Was the scientific quality of the included studies assessed and documented?
8. Was the scientific quality of the included studies used appropriately in formulating conclusions?
9. Were the methods used to combine the findings of studies appropriate?
10. Was the likelihood of publication bias assessed?
11. Was the conflict of interest stated?
*AMSTAR: Assessing the Methodological Quality of Systematic Reviews
The answer to all these questions was yes for all the included Cochrane Systematic Reviews wherever the questions were applicable
with the following questions. For question 4 the answer was ambiguous since all types of publication were searched and used where the
quality criteria for a trial were fulfilled and the criteria adequately reported. Question 9 was only applicable for the interventions for
which there was more than one trial of the same intervention (PE, IVIg and IFN beta-1a). Question 10 was not applicable in any of
the reviews because there were insufficient trials to create a meaningful funnel plot.
Table 2. Characteristics of excluded reviews
Reference Title Reason for exclusion
Bright 2013 Therapeutic options for chronic inflammatory de-
myelinating polyradiculoneuropathy: A systematic
review
No pre-determined objective
Cortese 2011 Evidence-based guideline update: Plasmapheresis
in neurologic disorders: Report of theTherapeutics
and Technology Assessment Subcommittee of the
AAN
No pre-determined objective
Donofrio 2009 Consensus statement: the use of intravenous im-
munoglobulin in the treatment of neuromuscular
conditions: report of the AANEMad hoc commit-
tee
No pre-determined objective
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Table 2. Characteristics of excluded reviews (Continued)
Elovaara 2008 EFNS guidelines for the use of intravenous im-
munoglobulin in treatment of neurological dis-
eases: EFNS task force on the use of intravenous
immunoglobulin in treatment of neurological dis-
eases
No pre-determined objective
Fergusson 2005 Use of intravenous immunoglobulin for treatment
of neurologic conditions: a systematic review
No pre-determined objective
Lacks largest IVIg trial
Gaebel 2009; Gaebel 2010 Intravenous immunoglobulin for the treatment of
chronic inflammatory demyelinating polyradicu-
loneuropathy: a systematic review and meta-anal-
ysis
No pre-determined objective
Lehmann 2013 Treatment of chronic inflammatory demyelinating
polyradiculoneuropathy
Narrative review
Quotes CSRs
Patwa 2012 Evidence-based guideline:
intravenous immunoglobulin in the treatment of
neuromuscular disorders: report of the Therapeu-
tics and Technology Assessment Subcommittee of
the AAN
No pre-determined objective
Stübgen 2013 A review of the use of biological agents for
chronic inflammatory demyelinating polyradicu-
loneuropathy
Narrative review
Van den Bergh 2010 EFNS/PNS guideline on management of chronic
inflammatory demyelinating polyradiculoneu-
ropathy: Report of a joint task force of the EFNS
and PNS - First revision
No pre-determined objective
Quotes CSR
Vanasse 2013a Chronic inflammatory demyelinating polyneu-
ropathy (in children)
Narrative review. Quotes CSRs
Buehler 2015 Is there evidence for recommending specific intra-
venous immunoglobulin formulations? A system-
atic review of head-to-head randomized controlled
trials
No pre-determined objective
Racosta 2016 Subcutaneous vs intravenous immunoglobulin for
chronic auto-immune neuropathies: A meta-anal-
ysis
No pre-determined objective
AAN: American Academy of Neurology; AANEM: American Academy of Neuromuscular and Electrodiagnostic Medicine; CSR:
Cochrane Systematic Review; EFNS: European Federation of Neurological Societies; IVIg: intravenous immunoglobulin; PNS:
Peripheral Nerve Society
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Table 3. Randomised controlled trials
Comparison References
1 Prednisone versus supportive treatment alone Dyck 1982
2 Azathioprine and prednisone versus prednisone Dyck 1985
3 Plasma exchange versus sham exchange Dyck 1986
4 Plasma exchange versus sham exchange in neuropathy asso-
ciated with monoclonal gammopathy of undetermined signif-
icance
Dyck 1991
5 IVIg versus placebo Vermeulen 1993
6 Plasma exchange versusIVIg Dyck 1994
7 3,4-diaminopyridine versus placebo Russell 1995
8 Plasma exchange versus sham exchange Hahn 1996a
9 IVIg versus placebo Hahn 1996
10 IVIg versus placebo Thompson 1996
11 Interferon beta-1a versus placebo Hadden 1999
12 IVIg versus prednisolone Hughes 2001*; McCrone 2003
13 IVIg versus placebo Mendell 2001
14 IVIg versus placebo (ICE trial) Hughes 2008*; Hughes 2009; Merkies 2009; Bril 2010;
Merkies 2010; Deng 2012
15 Methotrexate versus placebo RMC 2009
16 Interferon beta-1a versus placebo Hughes 2010
17 Comparison of two different brands of IVIg Kuitwaard 2010
18 Daily prednisolone versusmonthly high dose dexametha-
sone (PREDICT trial)
Van Schaik 2010*; Eftimov 2012
19 IVIg versus intravenous methylprednisolone Nobile-Orazio 2015; Nobile-Orazio 2012*
20 IVIg versus corticosteroids Camdessanché 2014
21 Subcutaneous immunoglobulin versus placebo Harbo 2012; Markvardsen 2013*;Markvardsen 2012;
30Treatments for chronic inflammatory demyelinating polyradiculoneuropathy (CIDP): an overview of systematic reviews (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Table 3. Randomised controlled trials (Continued)
22 Lipoic acid versus placebo NCT00962429
23 Gullong tongluo capsule versus no treatment Hu 2009
Abbreviations: IVIg: intravenous immunoglobulin
*Primary reference where there is more than one reference. Trials are listed in order of publication of the primary reference.
Table 4. Trials in progress
Comparison Reference
1 Subcutaneous human immunoglobulin versus placebo Van Schaik 2016; NCT01545076
2 0.2 g/kg versus 0.4 g/kg subcutaneous human immunoglobulin Markvardsen 2016
3 Fingolimod versus placebo Hartung 2014; NCT01625182
4 Comparison of 2 different IVIg preparations Pouget 2016
5 IVIg maintenance versus IVIg taper Eftimov 2015
6 Dose-response trial of IVIg Kuitwaard 2016
A P P E N D I C E S
Appendix 1. DARE search strategy
(This database is no longer being updated)
#1 inflammatory near/3 demyelinating
#2 polyradiculoneuropath* or polyneuropath* or polyneuritis or polyradiculoneuritis
#3 #1 and #2 and chronic
#4 MeSH descriptor: [Polyradiculoneuropathy, Chronic Inflammatory Demyelinating] this term only
#5 cidp
#6 #3 or #4 or #5
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Appendix 2. MEDLINE (OvidSP) search strategy
Database: Epub Ahead of Print, In-Process & Other Non-Indexed Citations, Ovid MEDLINE(R) Daily and Ovid MEDLINE(R)
<1946 to Present>
Ovid MEDLINE(R) 1946 to October Week 3 2016
Search Strategy:
--------------------------------------------------------------------------------
1 randomized controlled trial.pt. (434179)
2 controlled clinical trial.pt. (91862)
3 randomized.ab. (374639)
4 placebo.ab. (180548)
5 drug therapy.fs. (1920922)
6 randomly.ab. (266035)
7 trial.ab. (389797)
8 groups.ab. (1652938)
9 or/1-8 (3932161)
10 exp animals/ not humans.sh. (4333932)
11 9 not 10 (3392288)
12 Polyradiculoneuropathy, Chronic Inflammatory Demyelinating/ (1147)
13 ((chronic adj3 inflammatory adj3 demyelinating adj3 polyradiculoneuropathy) or (chronic adj3 inflammatory adj3 demyelinating
adj3 polyneuropathy) or cidp).mp. (2341)
14 inflammatory demyelinating.tw. (4069)
15 (polyradiculoneuropath$3 or polyneuropath$3).tw. (13269)
16 (polyneuritis or polyradiculoneuritis).tw. (1979)
17 polyneuropathies/ or Polyradiculoneuropathy/ (8301)
18 or/15-17 (19443)
19 chronic disease.mp. (261544)
20 14 and 18 and 19 (329)
21 or/12-13,20 (2355)
22 11 and 21 (689)
23 meta-analysis/ (74900)
24 meta-analysis.pt. (74900)
25 (meta analy$ or metaanaly$ or meta?analy$).tw. (105559)
26 ((health technology adj5 assessment) or hta).tw. (4213)
27 (systematic adj3 review$).mp. (99105)
28 (systematic adj3 overview$).mp. (1148)
29 consensus development conference.pt. (10250)
30 practice guideline.pt. (22081)
31 or/23-30 (216633)
32 21 and 31 (53)
33 22 or 32 (710)
34 remove duplicates from 33 (688)
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Appendix 3. EMBASE (OvidSP) search strategy
Database: Embase <1980 to 2016 Week 44>
Search Strategy:
--------------------------------------------------------------------------------
1 crossover-procedure.sh. (53582)
2 double-blind procedure.sh. (136356)
3 single-blind procedure.sh. (26668)
4 randomized controlled trial.sh. (458122)
5 (random$ or crossover$ or cross over$ or placebo$ or (doubl$ adj blind$) or allocat$).tw,ot. (1336628)
6 trial.ti. (212638)
7 or/1-6 (1492367)
8 (animal/ or nonhuman/ or animal experiment/) and human/ (1706635)
9 animal/ or nonanimal/ or animal experiment/ (3726774)
10 9 not 8 (3023844)
11 7 not 10 (1379659)
12 limit 11 to embase (487876)
13 (inflammatory adj3 demyelinating).tw. (6641)
14 (polyradiculoneuropath$3 or polyneuropath$3).tw. (18603)
15 polyneuropathies/ or Polyradiculoneuropathy/ (13564)
16 (polyneuritis or polyradiculoneuritis).tw. (1868)
17 or/14-16 (25476)
18 chronic disease.tw. or Chronic Disease/ (195443)
19 13 and 17 and 18 (130)
20 chronic inflammatory demyelinating polyneuropathy/ (2481)
21 (chronic adj3 inflammatory adj3 demyelinating adj3 polyradiculoneur$).tw. (1033)
22 cidp.mp. (2425)
23 or/19-22 (3977)
24 12 and 23 (111)
25 meta analysis/ (150972)
26 (meta analy$ or metaanaly$ or meta?analy$).mp. (191601)
27 biomedical technology assessment/ (11790)
28 ((health technology adj5 assessment) or hta).mp. (6410)
29 (systematic adj3 review$).mp. (181811)
30 or/25-29 (307392)
31 23 and 30 (79)
32 11 and 23 (284)
33 31 or 32 (334)
34 remove duplicates from 33 (314)
Appendix 4. CINAHL Plus (EBSCOhost) search strategy
Monday, October 31, 2016 10:07:55 AM
S41 S32 OR S38 Limiters - Exclude MEDLINE records
Search modes - Boolean/Phrase 3
S40 S32 OR S38 Search modes - Boolean/Phrase 115
S39 Limiters - Exclude MEDLINE records
Search modes - Boolean/Phrase 2,266,641
S38 S31 AND S37 10
S37 S33 OR S34 OR S35 OR S36 87,988
S36 systematic N3 review* 67,411
S35 (MH ”Systematic Review“) 38,064
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S34 meta analy* or metaanaly* or meta-analy* 41,856
S33 (MH ”Meta Analysis“) 25,408
S32 S18 and S31 115
S31 S28 or S29 or S30 417
S30 chronic n3 inflammatory n3 demyelinating n3 polyradiculoneuropathy 136
S29 cidp 236
S28 S22 and S26 and S27 370
S27 chronic 187,251
S26 S23 or S24 or S25 5,113
S25 polyradiculoneuropath* or polyneuropath* or polyneuritis 2,005
S24 (MH ”Polyneuritis+“) 331
S23 (MH ”Polyradiculoneuritis+“) or (MH ”Polyradiculopathy“) 3,493
S22 S21 or (S19 and S20) 676
S21 inflammatory n3 demyelinating 583
S20 TI inflammatory or AB inflammatory 44,115
S19 (MH ”Demyelinating Diseases“) 1,225
S18 S1 or S2 or S3 or S4 or S5 or S6 or S7 or S8 or S9 or S10 or S11 or S12 or S13 or S14 or S15 or S16 or S17 862,610
S17 ABAB design* 92
S16 TI random* or AB random* 180,834
S15 ( TI (cross?over or placebo* or control* or factorial or sham? or dummy) ) or ( AB (cross?over or placebo* or control* or factorial
or sham? or dummy) ) 358,285
S14 ( TI (clin* or intervention* or compar* or experiment* or preventive or therapeutic) or AB (clin* or intervention* or compar* or
experiment* or preventive or therapeutic) ) and ( TI (trial*) or AB (trial*) ) 130,719
S13 ( TI (meta?analys* or systematic review*) ) or ( AB (meta?analys* or systematic review*) ) 49,432
S12 ( TI (single* or doubl* or tripl* or trebl*) or AB (single* or doubl* or tripl* or trebl*) ) and ( TI (blind* or mask*) or AB (blind*
or mask*) ) 27,819
S11 PT (”clinical trial“ or ”systematic review“) 131,814
S10 (MH ”Factorial Design“) 984
S9 (MH ”Concurrent Prospective Studies“) or (MH ”Prospective Studies“) 290,556
S8 (MH ”Meta Analysis“) 25,408
S7 (MH ”Solomon Four-Group Design“) or (MH ”Static Group Comparison“) 50
S6 (MH ”Quasi-Experimental Studies“) 8,041
S5 (MH ”Placebos“) 9,846
S4 (MH ”Double-Blind Studies“) or (MH ”Triple-Blind Studies“) 34,078
S3 (MH ”Clinical Trials+“) 203,602
S2 (MH ”Crossover Design“) 14,009
S1 (MH”RandomAssignment“) or (MH”RandomSample“) or (MH”Simple RandomSample“) or (MH”StratifiedRandomSample“)
or (MH ”Systematic Random Sample“) 73,894
Appendix 5. Cochrane Neuromuscular Specialised Register (CRS) search strategy
#1 MeSH DESCRIPTOR Polyradiculoneuropathy, Chronic Inflammatory Demyelinating [REFERENCE] [STANDARD]
#2 (chronicNEAR3 inflammatoryNEAR3demyelinatingNEAR3polyradiculoneuropathy) or (chronicNEAR3 inflammatoryNEAR3
demyelinating NEAR3 polyneuropathy) or cidp [REFERENCE] [STANDARD]
#3 ”inflammatory demyelinating“ [REFERENCE] [STANDARD]
#4 polyradiculoneuropathy or polyneuropathy or polyradiculoneuropathies or polyneuropathies [REFERENCE] [STANDARD]
#5 polyneuritis or polyradiculoneuritis [REFERENCE] [STANDARD]
#6 MeSH DESCRIPTOR Polyneuropathies [REFERENCE] [STANDARD]
#7 MeSH DESCRIPTOR Polyradiculoneuropathy [REFERENCE] [STANDARD]
#8 #4 or #5 or #6 or #7 [REFERENCE] [STANDARD]
#9 ”chronic disease“ [REFERENCE] [STANDARD]
#10 #3 and #8 and #9 [REFERENCE] [STANDARD]
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#11 #1 or #2 or #10 [REFERENCE] [STANDARD]
#12 (#1 or #2 or #10) AND (INREGISTER) [REFERENCE] [STANDARD]
Appendix 6. CENTRAL (CRSO) search strategy
#1 (inflammatory near3 demyelinating):TI,AB,KY
#2 (polyradiculoneuropath* or polyneuropath* or polyneuritis or polyradiculoneuritis):TI, AB, KY
#3 #1 and #2 and chronic
#4 MESH DESCRIPTOR Polyradiculoneuropathy, Chronic Inflammatory Demyelinating
#5 cidp:TI,AB,KY
#6 #3 OR #4 OR #5
Appendix 7. Additional methods (as described in the protocol)
Where comparable data and outcomes existed for different treatments, we would have performed indirect comparisons between them
using a network analysis and multiple treatments meta-analysis if appropriate (White 2011b). We would have judged formal multiple
treatmentsmeta-analysis to be appropriate if the reviews had included the same outcome in any meta-analyses and if the trial populations
had been broadly comparable in age, gender, diagnostic criteria, disease duration and disease severity. We would have accepted limited
variation in these parameters, provided that there had been some overlap. For example, if all participants in one meta-analysis had had
’mild’ disease and those in another all ’moderate’, then we would not have combined them formally. However, if the mixtures had
been something like 30:70 in one meta-analysis and 70:30 in another, then we would have combined them but expressed the need for
caution in interpretation. To be considered comparable the outcomes should have been measured in clinically equivalent ways in each
meta-analysis over clinically similar periods of follow-up. In fact no indirect comparisons by network analysis were possible because of
a lack of shared outcomes and outcome intervals with the different interventions.
The method of White 2011b places multiple-treatment meta-analysis within the wider context of multivariate meta-analysis. Our
approach would have paralleled that described byWhite for his analysis combining data from 24 RCTs assessing four different smoking
cessation interventions . We would have first fitted so-called ’consistency’ models that assumed no design-by-treatment interactions
and used these to estimate pairwise treatment differences (with 95% confidence intervals (CIs)) and between-studies heterogeneity.
We would then have fitted ’inconsistency models’ to assess the level of evidence for design-by-treatment interactions. If there had been
evidence of such interactions then we would have sought to explain these using any relevant factors that differed between studies. As
an example, consider three treatments A, B and C for which trials that directly compare A with B favour A, and trials that directly
compare A with C favour C, but trials that compare B with C favour B. The data are contradictory unless one can identify a factor
that explains the apparent discrepancy. For instance, if C is be the best treatment in “severe” cases, but the worst in “mild” cases,
and the trials comparing A with C had been carried out predominantly in “severe” cases, but those comparing B with C had been
carried out predominantly in “mild” cases, then this could explain the discrepancy. If there had been unexplainable design-by-treatment
interactions, then our interpretation would have been suitably cautious.
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